1
|
Otomi Y, Shinya T, Kasai H, Okada N, Matsushita T, Higashi K, Matsuzaki S, Hiroshima Y, Kubo M, Otsuka H, Harada M. Axillary Lymph Node Uptake on 18F-FDG PET/CT after COVID-19 Vaccination: A Direct Comparison Study with Influenza Vaccination. Mol Imaging Radionucl Ther 2023; 32:13-19. [PMID: 36817634 PMCID: PMC9950671 DOI: 10.4274/mirt.galenos.2022.27136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023] Open
Abstract
Objectives To compare vaccinated-side axillary lymph node uptake on 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) after coronavirus disease-2019 (COVID-19) and influenza vaccination. Methods We retrospectively analyzed 177 patients who underwent 18F-FDG PET/CT after COVID-19 or influenza vaccination. We compared the uptake of the vaccinated-side axillary lymph nodes of 109 COVID-19 vaccinated patients with those of a lot of influenza-vaccinated patients. We also compared the uptake between 66 patients who received the first COVID-19 vaccination with 43 who received the second COVID-19 vaccination. Results 18F-FDG-avid axillary lymph nodes on the vaccinated side were significantly more frequently observed in the COVID-19 group (45%) than in the influenza group (19%) (p<0.001). When the interval between vaccination to PET/CT was within 7 days, there was no significant difference in the frequency of 18F-FDG-avid vaccinated-side axillary lymph nodes between the groups (COVID-19 group: 41% vs. influenza group: 45%, p=0.724). When the interval was over 7 days, 18F-FDG-avid lymph nodes were much more frequent in the COVID-19 group (47%) than in the influenza group (7%) (p<0.001). Comparing the first and second COVID-19 groups, 18F-FDG-avid lymph nodes were more frequent in the second vaccination group than in the first vaccination group, but the difference was not significant. Conclusion 18F-FDG-avid vaccinated-side axillary lymph nodes were more frequently observed in the COVID-19 group than in the influenza group. In the case of the COVID-19 vaccine, a delay of 18F-FDG PET/CT examination is recommended by a longer interval from vaccination than in the influenza vaccine.
Collapse
Affiliation(s)
- Yoichi Otomi
- Tokushima University Hospital, Department of Radiology, Tokushima, Japan
| | - Takayoshi Shinya
- Tokushima University Hospital, Department of Radiology, Tokushima, Japan
| | - Hiroto Kasai
- Tokushima University Hospital, Department of Radiology, Tokushima, Japan
| | - Naoko Okada
- Tokushima Prefectural Central Hospital, Department of Radiology, Tokushima, Japan
| | - Tomoki Matsushita
- Tokushima University Hospital, Department of Radiology, Tokushima, Japan
| | - Kohei Higashi
- Tokushima University Hospital, Department of Radiology, Tokushima, Japan
| | - Saya Matsuzaki
- Tokushima University Hospital, Department of Radiology, Tokushima, Japan
| | - Yuka Hiroshima
- Tokushima University Hospital, Department of Radiology, Tokushima, Japan
| | - Michiko Kubo
- Tokushima University Hospital, Department of Radiology, Tokushima, Japan
| | - Hideki Otsuka
- Tokushima University Hospital, Department of Radiology, Tokushima, Japan
| | - Masafumi Harada
- Tokushima University Hospital, Department of Radiology, Tokushima, Japan
| |
Collapse
|
2
|
Otomi Y, Arai Y, Otomo M, Irahara S, Terazawa K, Kubo M, Abe T, Shinya T, Otsuka H, Harada M. Increased physiological [18F]FDG uptake in the liver and blood pool among patients with impaired renal function. Nucl Med Rev Cent East Eur 2022; 25:95-100. [PMID: 35848547 DOI: 10.5603/nmr.a2022.0021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2021] [Accepted: 06/22/2022] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND In the daily clinical course, the liver uptake may seem to be increased in patients with renal failure. The purpose of this study was to investigate whether or not the FDG uptake of the liver, and the FDG uptake of blood pool which is generally used as a reference site as well as liver, is increased in patients with renal failure. MATERIAL AND METHODS We retrospectively analyzed 233 patients who underwent FDG positron emission tomography/computed tomography (PET/CT). Renal failure is defined as an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2. We compared the FDG uptake in the liver and mediastinal blood pool of 67 patients with impaired renal function to that in 166 patients with a normal renal function (eGFR ≥ 60 mL/min/1.73 m2). Correlations between the liver or mediastinal blood pool FDG uptake and the eGFR were also analyzed by Spearman's correlation test. RESULTS Maximum and mean standardized uptake values (SUVmax and SUVmean, respectively) of the liver and the SUVmean of the mediastinal blood pool were 3.48 ± 0.57, 2.56 ± 0.37, and 1.90 ± 0.28 in the impaired renal function group, respectively, and 3.13 ± 0.45, 2.29 ± 0.33, and 1.66 ± 0.23, in the normal group, respectively. The SUVmax and SUVmean of the liver and SUVmean of the mediastinal blood pool in the impaired renal function group were significantly higher than those in the normal group (p < 0.001, < 0.001, and < 0.001, respectively). The SUVmax and SUVmean of the liver and SUVmean of the mediastinal blood pool of patients showed a significant negative correlation with the eGFR (Spearman's p = -0.25, -0.30, and -0.40, respectively, each p < 0.001). CONCLUSIONS FDG uptake in both the liver and mediastinal blood pool was higher in patients with impaired renal function.
Collapse
Affiliation(s)
- Yoichi Otomi
- Department of Radiology, Tokushima University, Tokushima City, Japan.
| | - Yuta Arai
- Department of Radiology, Tokushima University, Tokushima City, Japan
| | - Maki Otomo
- Department of Radiology, Tokushima University, Tokushima City, Japan
| | - Saho Irahara
- Department of Radiology, Tokushima University, Tokushima City, Japan
| | - Kaori Terazawa
- Department of Radiology, Tokushima University, Tokushima City, Japan
| | - Michiko Kubo
- Department of Radiology, Tokushima University, Tokushima City, Japan
| | - Takashi Abe
- Department of Radiology, Nagoya University Hospital, Nagoya City, Japan
| | - Takayoshi Shinya
- Department of Radiology, Tokushima University, Tokushima City, Japan
| | - Hideki Otsuka
- Department of Radiology, Tokushima University, Tokushima City, Japan
| | - Masafumi Harada
- Department of Radiology, Tokushima University, Tokushima City, Japan
| |
Collapse
|
3
|
Kinoshita N, Nawata T, Okuda S, Kubo M, Wada Y, Kobayashi S, Tanaka N, Yano M. Cardiac phenotypes in the acute-phase of microscopic polyangiitis involves dilatation of the left atrium caused by LV diastolic dysfunction. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2756] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Microscopic polyangiitis (MPA) is a type of primary systemic vasculitis that affects various organs, especially the lungs and kidneys. However, few reports regarding cardiac features of MPA patients were found.
Purpose
We aim to investigate the echocardiographic parameters of acute-phase MPA.
Methods and results
This single-center retrospective study included 15 patients with MPA (Mean age at 72.2±7.1 years, women 73.3%) who underwent echocardiography within two weeks of commencing steroid therapy for induction or reinduction. The echocardiography parameters of the patients were compared with those of 30 age and sex-matched controls. In the MPA group, the commonly affected organs were kidneys (93.3%) and lungs (46.7%); 5 patients (33.3%) had a history of hypertension, which had a similar frequency as the control group. No significant difference in left ventricular (LV) diameter, LV ejection fraction, e', or inferior vena cava diameter was observed between the two groups. However, the MPA group showed significantly higher left atrial (LA) diameter (p=0.033) and LA volume index (p=0.001), as well as higher early diastolic filling velocity (E-wave, p=0.015; E/A, p=0.043; E/e', p=0.041), diastolic pulmonary venous flow velocity (p=0.013), trans-tricuspid pressure gradient (p=0.019), and shorter deceleration time (p=0.038), associated with mildly thicker ventricular walls of left ventricle (LV) than the control group. Moreover, serum levels of C-reactive protein showed significant correlation between E wave (r=0.58, p=0.023), E/A (r=0.67, p=0.006), and deceleration time (r=−0.69, p=0.005) in the MPA group. These results may indicate that in MPA, increased LV stiffness, rather than impairment of LV relaxation was contributed to LV diastolic function, resulting in LA enlargement.
Conclusion
Patients with acute-phase MPA had LA dilatation associated with LV diastolic dysfunction. This finding indicates the importance of cardiac assessment in patients with MPA.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- N Kinoshita
- Yamaguchi University Graduate School of Medicine, Department of Medicine and Clinical Science, Ube, Japan
| | - T Nawata
- Yamaguchi University Graduate School of Medicine, Department of Medicine and Clinical Science, Ube, Japan
| | - S Okuda
- Yamaguchi University Graduate School of Medicine, Department of Medicine and Clinical Science, Ube, Japan
| | - M Kubo
- Yamaguchi University Graduate School of Medicine, Department of Medicine and Clinical Science, Ube, Japan
| | - Y Wada
- Yamaguchi University Graduate School of Medicine, Department of Medicine and Clinical Science, Ube, Japan
| | - S Kobayashi
- Yamaguchi University Graduate School of Medicine, Department of Medicine and Clinical Science, Ube, Japan
| | - N Tanaka
- Yamaguchi University Graduate School of Medicine, Department of Medicine and Clinical Science, Ube, Japan
| | - M Yano
- Yamaguchi University Graduate School of Medicine, Department of Medicine and Clinical Science, Ube, Japan
| |
Collapse
|
4
|
Diekstra M, Swen J, van der Zanden L, Vermeulen S, Boven E, Mathijssen R, Oskarsdottir A, Oosterwijk E, Cambon-Thomsen A, Castellano D, Fritsch A, Garcia-Donas J, Rodriguez-Antona C, Jaehde U, Rafnar T, Stefansson K, Bohringer S, Kubo M, Kiemeney L, Guchelaar HJ. 685P Genome-wide association meta-analysis identifies novel variants that correlate with efficacy outcomes in sunitinib-treated patients with metastatic renal cell carcinoma. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
5
|
Saiki R, Momozawa Y, Nannya Y, Nakagawa M, Ochi Y, Yoshizato T, Terao C, Kuroda Y, Shiraishi Y, Chiba K, Tanaka H, Niida A, Imoto S, Matsuda K, Morisaki T, Murakami Y, Kamatani Y, Matsuda S, Kubo M, Miyano S, Makishima H, Ogawa S. Topic: AS04-MDS Biology and Pathogenesis/AS04a-Normal, MDS, and leukemic stem cells. Leuk Res 2021. [DOI: 10.1016/j.leukres.2021.106679.3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
6
|
Wang F, Trier A, Li F, Kim S, Chen Z, Chai J, Mack M, Morrison S, Hamilton J, Baek J, Yang T, Heul AMV, Xu A, Xie Z, Dong X, Kubo M, Hu H, Hsieh C, Dong X, Liu Q, Margolis D, Ardeleanu M, Miller M, Kim B. 201 A basophil-neuronal axis promotes itch. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
7
|
Kubo M, Mizutani T, Shimizu K, Matsumoto M, Iizuka K. New methods for determination of the keyhole position in the lateral suboccipital approach to avoid transverse-sigmoid sinus injury: Proposition of the groove line as a new surgical landmark. Neurochirurgie 2021; 67:325-329. [PMID: 33450265 DOI: 10.1016/j.neuchi.2020.12.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 11/15/2020] [Accepted: 12/25/2020] [Indexed: 11/18/2022]
Abstract
PURPOSE The asterion is frequently used as an anatomical landmark to determine the location of a keyhole in the lateral suboccipital approach used in craniotomies. However, the asterion may not be ideal because of large individual differences among patients. We examined a simple and safe method for determining an optimal keyhole position (KP) using the digastric groove as a new landmark in the lateral suboccipital approach. METHODS Thirty-three patients with trigeminal neuralgia who underwent surgery in our institute between April 2014 and December 2018 were included. The groove line (GL) was designed accurately, extending the digastric groove on the surface of the occipital bone, as the x-axis. The y-axis was depicted from the posterior edge of the digastric groove (the groove point: GP) vertical to the GL. The x-y coordinates represented the distances from GP on each axis. The x-y coordinates of median edge of the transverse-sigmoid sinus (TSJ point), asterion, and the intersection of the GL and transverse sinus (the transverse point: TP) were investigated, based on intraoperative findings and recorded videos. RESULTS The x-y coordinated of the TSJ point were (23.9±3.9, 7.2±3.6). In all patients, the TSJ point was located superior to the GL. The x-y coordinates of the asterion were (27.3±6.0, 8.9±4.1), and in 28 of the 33 patients, their coordinates exceeded the TSJ points. The x-coordinate of the TP was 29.5±4.5, and was located behind the TSJ point on the GL in all patients. The shortest distance between the TSJ points and TP was approximately 3mm. According to these measurements, we decided that the optimal KP would be at 20mm from the GP, subjacent to the GL. CONCLUSIONS Our methods of using the GL as a new surgical landmark for setting the optimal KP is simple, safe, and useful.
Collapse
Affiliation(s)
- M Kubo
- Department of neurosurgery, Showa university school of medicine, 1-5-8 Hatanodai, 142-8555 Tokyo, Shinagawa, Japan.
| | - T Mizutani
- Department of neurosurgery, Showa university school of medicine, 1-5-8 Hatanodai, 142-8555 Tokyo, Shinagawa, Japan
| | - K Shimizu
- Department of neurosurgery, Showa university school of medicine, 1-5-8 Hatanodai, 142-8555 Tokyo, Shinagawa, Japan
| | - M Matsumoto
- Department of neurosurgery, Showa university school of medicine, 1-5-8 Hatanodai, 142-8555 Tokyo, Shinagawa, Japan
| | - K Iizuka
- Department of neurosurgery, Showa university school of medicine, 1-5-8 Hatanodai, 142-8555 Tokyo, Shinagawa, Japan
| |
Collapse
|
8
|
Shinya T, Otomi Y, Nishisho T, Beuthien-Baumann B, Kubo M, Otsuka H, Bando Y, Yanagawa H, Sairyo K, Harada M. Preliminary clinical assessment of dynamic carbon-11 methionine positron-emission tomography/computed tomography for the diagnosis of the pathologies in patients with musculoskeletal lesions: a prospective study. Eur J Hybrid Imaging 2020; 4:15. [PMID: 34191157 PMCID: PMC8218133 DOI: 10.1186/s41824-020-00083-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2020] [Accepted: 07/21/2020] [Indexed: 11/10/2022] Open
Abstract
Background This study prospectively assessed the diagnostic capacity of dynamic carbon-11 methionine (C-11 MET) positron-emission tomography (PET)/computed tomography for the diagnosis of pathologies in patients with primary unknown musculoskeletal lesions (MSLs). In total, 13 patients with MSLs underwent dynamic scans (5–10 [phase 1], 10–15 [phase 2], 15–20 [phase 3], 20–25 [phase 4], 25–30 [phase 5], and 30–35 [phase 6] min post-injection of C-11 MET). We statistically compared the maximum standardised uptake values (SUVmax) and corresponding retention index for dynamic scans (RI-SUV) for five benign MSLs (BMSLs), five primary malignant musculoskeletal tumours (PMMSTs), four metastatic musculoskeletal tumours (MMSTs), and three malignant lymphoma (ML) cases and explored their diagnostic capacities using receiver operating characteristic (ROC) curve analyses. Results SUVmax gradually decreased or remained similar with minimal fluctuations in all BMSL cases and four of five PMMST cases. In contrast, SUVmax increased over time in one case of PMMST and in all cases of MMST and ML. Significant differences were observed in SUVmax for all time phases and RI-SUV between BMSLs and MMSLs, in SUVmax for all time phases between PMMSTs and BMSLs, in SUVmax for all time phases and RI-SUV between non-PMMST-malignant tumours and BMSL, and in RI-SUV between non-PMMST-malignant tumours and PMMST. In ROC analyses, the areas under the curve yielded the highest values at 1.00 for differentiating most intergroup comparisons. Conclusions Dynamic C-11 MET PET scans have the potential to be good predictors of discriminating MSLs in patients with primary unknown MSLs in clinical practice.
Collapse
Affiliation(s)
- Takayoshi Shinya
- Department of Radiology, Tokushima University Hospital, 2-50-1, Kuramoto-cho, Tokushima City, Tokushima, 770-8503, Japan. .,Division of Radiology, German Cancer Research Centre (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany. .,Department of Diagnostic and Therapeutic Radiology, Kawasaki Medical School General Medical Centre, 2-6-2 Nakasange, Kita-ku, Okayama City, Okayama, 700-8505, Japan.
| | - Yoichi Otomi
- Department of Radiology, Tokushima University Hospital, 2-50-1, Kuramoto-cho, Tokushima City, Tokushima, 770-8503, Japan
| | - Toshihiko Nishisho
- Department of Orthopedics, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima City, Tokushima, 770-8503, Japan
| | - Bettina Beuthien-Baumann
- Division of Radiology, German Cancer Research Centre (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany
| | - Michiko Kubo
- Department of Radiology, Tokushima University Hospital, 2-50-1, Kuramoto-cho, Tokushima City, Tokushima, 770-8503, Japan
| | - Hideki Otsuka
- Department of Medical Imaging/Nuclear Medicine, Institute of Biomedical Sciences, Tokushima University Graduate School, 2-50-1, Kuramoto-cho, Tokushima City, Tokushima, 770-8503, Japan
| | - Yoshimi Bando
- Division of Pathology, Tokushima University Hospital, 2-50-1, Kuramoto-cho, Tokushima City, Tokushima, 770-8503, Japan
| | - Hiroaki Yanagawa
- Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital, 2 Kuramoto-cho, Tokushima City, Tokushima, 770-8503, Japan
| | - Koichi Sairyo
- Department of Orthopedics, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima City, Tokushima, 770-8503, Japan
| | - Masafumi Harada
- Department of Radiology, Tokushima University Hospital, 2-50-1, Kuramoto-cho, Tokushima City, Tokushima, 770-8503, Japan
| |
Collapse
|
9
|
Hirai N, Kubo M, Sakurai Y, Komatsuzaki K, Tazawa R. 0205 Remote Collection of Daily Life Information for Japanese Residents. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Japanese medical students spend their school days under a dense curriculum. It is often difficult to maintain their healthy lifestyle. After graduation, most of them participate in clinical training programs as residents. It is also difficult to maintain a normal life because they are engaged in different specialized departments every few months. Such an environment is considered prone to mental health problems. In fact, one in four residents are reported to be newly depressed two months after the start of clinical training (Maeno T, et al. 2008). These mental health issues are thought to be affected by changes in daily life, but it is difficult to know such changes. In order to investigate changes in their daily lives, we developed a data collection system related to mental health via the Internet.
Methods
The subjects were 22 medical students who graduated from our university in March 2017. They were asked to wear activity tracker wrist bands from December 2016. They were also asked to answer the questionnaire on a web site every week as much as possible, and the responses were collected via the Internet together with the activity data. The first eight months of the observation period, including four months before the start of clinical training and four month after the start of clinical training, are divided into four quarters every two months, and the averaged sleep time and responses to the questionnaire in each period were investigated.
Results
The average number of days that the sleep was effectively recorded during each two months was 28–48. The average number of responses to the questionnaire during each two months was 6.0–7.2.
Conclusion
Residents in the initial clinical training period should be very busy, but the system we have developed seems to have worked well with them for the first four months after the start of clinical training. Whether this system would work as well a longer period is a further problem.
Support
This study is supported by KAKENHI 16K01753.
Collapse
Affiliation(s)
- N Hirai
- Tokyo Medical and Dental University, Tokyo, JAPAN
| | - M Kubo
- Tokyo Medical and Dental University, Tokyo, JAPAN
| | - Y Sakurai
- Tokyo Medical and Dental University, Tokyo, JAPAN
| | | | - R Tazawa
- Tokyo Medical and Dental University, Tokyo, JAPAN
| |
Collapse
|
10
|
Umehata H, Fumagalli M, Smail I, Matsuda Y, Swinbank AM, Cantalupo S, Sykes C, Ivison RJ, Steidel CC, Shapley AE, Vernet J, Yamada T, Tamura Y, Kubo M, Nakanishi K, Kajisawa M, Hatsukade B, Kohno K. Gas filaments of the cosmic web located around active galaxies in a protocluster. Science 2019; 366:97-100. [DOI: 10.1126/science.aaw5949] [Citation(s) in RCA: 63] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2019] [Accepted: 09/02/2019] [Indexed: 11/02/2022]
Affiliation(s)
- H. Umehata
- RIKEN Cluster for Pioneering Research, 2-1 Hirosawa, Wako-shi, Saitama 351-0198, Japan
- Institute of Astronomy, School of Science, The University of Tokyo, 2-21-1 Osawa, Mitaka, Tokyo 181-0015, Japan
| | - M. Fumagalli
- Centre for Extragalactic Astronomy, Department of Physics, Durham University, South Road, Durham DH1 3LE, UK
- Institute for Computational Cosmology, Durham University, South Road, Durham DH1 3LE, UK
- Dipartimento di Fisica G. Occhialini, Università degli Studi di Milano Bicocca, Piazza della Scienza 3, 20126 Milano, Italy
| | - I. Smail
- Centre for Extragalactic Astronomy, Department of Physics, Durham University, South Road, Durham DH1 3LE, UK
| | - Y. Matsuda
- National Astronomical Observatory of Japan, 2-21-1 Osawa, Mitaka, Tokyo 181-8588, Japan
- Department of Astronomy, School of Science, SOKENDAI (The Graduate University for Advanced Studies), Osawa, Mitaka, Tokyo 181-8588, Japan
| | - A. M. Swinbank
- Centre for Extragalactic Astronomy, Department of Physics, Durham University, South Road, Durham DH1 3LE, UK
| | - S. Cantalupo
- Department of Physics, ETH Zurich, Wolfgang-Pauli-Strasse 27, 8093 Zurich, Switzerland
| | - C. Sykes
- Centre for Extragalactic Astronomy, Department of Physics, Durham University, South Road, Durham DH1 3LE, UK
- Institute for Computational Cosmology, Durham University, South Road, Durham DH1 3LE, UK
| | - R. J. Ivison
- European Southern Observatory, Karl-Schwarzschild-Str. 2, D-85748 Garching, Germany
- Institute for Astronomy, University of Edinburgh, Royal Observatory, Blackford Hill, Edinburgh EH9 3HJ, UK
| | - C. C. Steidel
- Cahill Center for Astronomy and Astrophysics, California Institute of Technology, MS 249-17, Pasadena, CA 91105, USA
| | - A. E. Shapley
- Department of Physics and Astronomy, University of California, Los Angeles, 430 Portola Plaza, Los Angeles, CA 90095, USA
| | - J. Vernet
- European Southern Observatory, Karl-Schwarzschild-Str. 2, D-85748 Garching, Germany
| | - T. Yamada
- Institute of Space and Aeronautical Science, Japanese Aerospace Exploration Agency, 3-1-1, Yoshinodai, Chuo-ku, Sagamihara, Kanagawa 252-5210, Japan
| | - Y. Tamura
- Division of Particle and Astrophysical Science, Graduate School of Science, Nagoya University, Nagoya 464-8602, Japan
| | - M. Kubo
- National Astronomical Observatory of Japan, 2-21-1 Osawa, Mitaka, Tokyo 181-8588, Japan
| | - K. Nakanishi
- National Astronomical Observatory of Japan, 2-21-1 Osawa, Mitaka, Tokyo 181-8588, Japan
- Department of Astronomy, School of Science, SOKENDAI (The Graduate University for Advanced Studies), Osawa, Mitaka, Tokyo 181-8588, Japan
| | - M. Kajisawa
- Research Center for Space and Cosmic Evolution, Ehime University, Bunkyo-cho 2-5, Matsuyama 790-8577, Japan
| | - B. Hatsukade
- Institute of Astronomy, School of Science, The University of Tokyo, 2-21-1 Osawa, Mitaka, Tokyo 181-0015, Japan
| | - K. Kohno
- Institute of Astronomy, School of Science, The University of Tokyo, 2-21-1 Osawa, Mitaka, Tokyo 181-0015, Japan
| |
Collapse
|
11
|
Kawaji H, Kubo M, Motoyama Y, Shimazaki A, Hayashi S, Kurata K, Yamada M, Kaneshiro K, Kai M, Nakamura M. Functional analysis of tumour infiltrating lymphocytes in triple negative breast cancer focusing on granzyme B. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz238.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
12
|
Thompson MC, Wolff AM, Nango E, Kubo M, Young ID, Nakane T, Sugahara M, Tanaka R, Ito K, Brewster AS, Sierra RG, Yumoto F, Nomura T, Owada S, Hino T, Tosha T, Tanaka T, Im D, Aquila A, Carbajo S, Koralek J, Yamashita A, Luo F, Boutet S, Sauter NK, Tono K, Iwata S, Fraser JS. Turning up the heat on dynamic proteins: observing molecular motion in real time with temperature-jump X-ray crystallography. Acta Crystallogr A Found Adv 2019. [DOI: 10.1107/s0108767319098349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
13
|
Magawa S, Nii M, Tanaka H, Furuhashi F, Maki S, Kubo M, Tanaka K, Kondo E, Ikeda T. Phase-1 clinical study of tadalafil administered for selective fetal growth restriction in twin pregnancy. J Matern Fetal Neonatal Med 2019; 34:1075-1082. [PMID: 31131648 DOI: 10.1080/14767058.2019.1624717] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
BACKGROUND Selective fetal growth restriction (sFGR) is a condition of twin pregnancy in which the development of one fetus is restricted, despite normal growth of the other fetus. A method of intrauterine therapy for sFGR does not currently exist. The only treatment for sFGR is to terminate the pregnancy before the FGR worsens. In twin pregnancies, maternal and intrauterine environments are common in both fetuses, thus a placental factor is considered the cause of FGR in fetuses. Tadalafil is a phosphodiesterase (PDE)-5 inhibitor that induces an increase in uterine blood flow by dilatation of blood vessels in cases of FGR with placental dysfunction, which improves FGR. PURPOSE The aim of this study was to investigate the safety and maximum tolerated dose (MTD) of tadalafil administered for twin pregnancy (diamniotic-monochorionic twin or diamniotic-dichorionic twin). METHODS In this phase I, open-label, dose-escalation trial, sequential patient cohorts (3 + 3 dose-escalation design) for twin pregnancy received tadalafil (20 or 40 mg/d) as a single dose by oral administration from the day they were diagnosed with sFGR, defined as estimated fetal weight (EFW) < 3% tiles, that is, -1.8 SD the mean EFW for gestational age (GA) to unacceptable toxicity or the day of delivery. This study evaluated the safety of maternally administered tadalafil for sFGR, examining maternal, fetal, and neonatal adverse events. Maternal adverse events were graded on the basis of the Common Terminology Criteria for Adverse Events v4.0. RESULTS Six women with sFGR who were pregnant with twins were treated with tadalafil. There were no severe adverse events in either cohort, although the most common (≥3 patients) drug-related adverse events were headache and heart failure. The MTD of tadalafil among Japanese patients was 40 mg. CONCLUSIONS Tadalafil has a manageable safety profile up to an MTD of 40 mg/d.
Collapse
Affiliation(s)
- Shoichi Magawa
- Faculty of Medicine, Department of Obstetrics and Gynecology, Mie University, Tsu, Mie, Japan
| | - Masafumi Nii
- Faculty of Medicine, Department of Obstetrics and Gynecology, Mie University, Tsu, Mie, Japan
| | - Hiroaki Tanaka
- Faculty of Medicine, Department of Obstetrics and Gynecology, Mie University, Tsu, Mie, Japan
| | - Fumi Furuhashi
- Faculty of Medicine, Department of Obstetrics and Gynecology, Mie University, Tsu, Mie, Japan
| | - Shintaro Maki
- Faculty of Medicine, Department of Obstetrics and Gynecology, Mie University, Tsu, Mie, Japan
| | - Michiko Kubo
- Faculty of Medicine, Department of Obstetrics and Gynecology, Mie University, Tsu, Mie, Japan
| | - Kayo Tanaka
- Faculty of Medicine, Department of Obstetrics and Gynecology, Mie University, Tsu, Mie, Japan
| | - Eiji Kondo
- Faculty of Medicine, Department of Obstetrics and Gynecology, Mie University, Tsu, Mie, Japan
| | - Tomoaki Ikeda
- Faculty of Medicine, Department of Obstetrics and Gynecology, Mie University, Tsu, Mie, Japan
| |
Collapse
|
14
|
Shinya T, Otomi Y, Kubo M, Kinoshita M, Takechi K, Uyama N, Yamanaka M, Terazawa K, Toba H, Bando Y, Otsuka H, Harada M. Preliminary clinical assessment of dynamic 18F-fluorodeoxyglucose positron emission tomography/computed tomography for evaluating lymph node metastasis in patients with lung cancer: a prospective study. Ann Nucl Med 2019; 33:414-423. [PMID: 30911883 DOI: 10.1007/s12149-019-01350-z] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2018] [Accepted: 03/09/2019] [Indexed: 12/21/2022]
Abstract
OBJECTIVE We assessed the diagnostic capacity of dynamic fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and dual-time-point (DTP) PET/CT to explore the optimal scan timing for nodal staging in lung cancer. METHODS Thirty-four patients with lung cancer underwent dynamic and consecutive DTP PET/CT scans. Two readers visually evaluated FDG uptake within each lymph node (LN) and pulmonary artery (metastatic LN: n = 10; nonmetastatic LN: n = 121). For each dynamic and DTP scan, we compared the maximum standardized uptake value (SUVmax) and the retention index of the SUVmax (RI-SUVmax) between metastatic and nonmetastatic LNs. We compared the diagnostic capacity of the dynamic and DTP scans using receiver operating characteristic (ROC) analyses. RESULTS In the visual analyses of LN metastases, a sensitivity of 20.0-60.0% and specificity of 97.5-100.0% were identified for the first to third dynamic scans. The sensitivity of the 1-h early and 2-h delayed scans was 80.0% and 90.0%, respectively, whereas the specificity was 66.9% and 47.9%, respectively. The visual analysis of the dynamic second phase had the highest accuracy. Semiquantitative analyses revealed that the SUVmax was significantly higher for metastatic LNs than for nonmetastatic LNs in the dynamic second and third phases and the 1-h early and 2-h delayed phases (p < 0.05 for all). The RI-SUVmax was higher in metastatic LNs than in nonmetastatic LNs for the dynamic scan (p = 0.004) and the DTP scan (p = 0.002). The ROC analyses showed that SUV2 and SUV3 had higher performances with high specificity, high negative predictive value, and high accuracy than the other parameters. The area under the ROC curve of the RI-SUV-dual-time-point had the highest value (0.794) without any significant differences between the area under the ROC curves for all parameters (p > 0.05 for all). CONCLUSIONS Based on the visual and semiquantitative analyses, 18F-FDG dynamic PET/CT exhibited excellent performance with extremely high specificity in the dynamic second phase.
Collapse
Affiliation(s)
- Takayoshi Shinya
- Department of Radiology, Tokushima University Hospital, 2-50-1, Kuramoto-cho, Tokushima City, Tokushima, 770-8503, Japan.
| | - Yoichi Otomi
- Department of Radiology, Tokushima University Hospital, 2-50-1, Kuramoto-cho, Tokushima City, Tokushima, 770-8503, Japan
| | - Michiko Kubo
- Department of Radiology, Tokushima University Hospital, 2-50-1, Kuramoto-cho, Tokushima City, Tokushima, 770-8503, Japan
| | - Mitsuhiro Kinoshita
- Department of Radiology, Tokushima Red Cross Hospital, 103, Irinokuchi Komatsushima-cho, Komatsushima City, Tokushima, 773-8502, Japan
| | - Katsuya Takechi
- Department of Radiology, Tokushima Red Cross Hospital, 103, Irinokuchi Komatsushima-cho, Komatsushima City, Tokushima, 773-8502, Japan
| | - Naoto Uyama
- Department of Radiology, Tokushima Red Cross Hospital, 103, Irinokuchi Komatsushima-cho, Komatsushima City, Tokushima, 773-8502, Japan
| | - Moriaki Yamanaka
- Department of Radiology, Tokushima University Hospital, 2-50-1, Kuramoto-cho, Tokushima City, Tokushima, 770-8503, Japan
| | - Kaori Terazawa
- Department of Radiology, Tokushima University Hospital, 2-50-1, Kuramoto-cho, Tokushima City, Tokushima, 770-8503, Japan
| | - Hiroaki Toba
- Department of Thoracic and Endocrine Surgery and Oncology, Institute of Health Biosciences, Tokushima University Graduate School, 2-50-1, Kuramoto-cho, Tokushima City, Tokushima, 770-8503, Japan
| | - Yoshimi Bando
- Division of Pathology, Tokushima University Hospital, 2-50-1, Kuramoto-cho, Tokushima City, Tokushima, 770-8503, Japan
| | - Hideki Otsuka
- Department of Medical Imaging/Nuclear Medicine, Institute of Biomedical Sciences, Tokushima University Graduate School, 2-50-1, Kuramoto-cho, Tokushima City, Tokushima, 770-8503, Japan
| | - Masafumi Harada
- Department of Radiology, Tokushima University Hospital, 2-50-1, Kuramoto-cho, Tokushima City, Tokushima, 770-8503, Japan
| |
Collapse
|
15
|
Kai M, Mori H, Kawaji H, Kurata K, Yamada M, Kubo M, Nakamura M. Functional mechanism on tumor-infiltrating lymphocytes in triple-negative breast cancer. Breast 2019. [DOI: 10.1016/s0960-9776(19)30334-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
16
|
Kurata K, Kubo M, Mori H, Kawaji H, Motoyama Y, Kuroki L, Yamada M, Kaneshiro K, Kai M, Nakamura M. Abstract P1-06-11: Microsatellite instability in triple negative breast cancers. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-06-11] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:Microsatellite instability (MSI) is a phenotype resulting from defect in mismatch repair genes. The Food and Drug Administration approved anti-programmed death 1 (PD-1) immune checkpoint inhibitor for any solid tumor with MSI-high (MSI-H). Some tumors had good response to PD-1 blockade and it is a promising treatment for a part of refractory breast cancers. Our goal was to determine the frequency of MSI in triple negative breast cancer (TNBC), one of the most clinically aggressive subtypes.
Patients and Methods:This study included 228 patients with primary TNBC underwent resection without neoadjuvant chemotherapy between January 2004 and December 2014. Genomic DNA was extracted from formalin-fixed and paraffin-embedded tissue. Tumor and control DNA were amplified by polymerase chain reaction at the following 5 microsatellite markers: NR-21, BAT-26, BAT-25, NR-24, MONO-27. We classified the tumors as microsatellite stable(MSS), MSI-low or MSI-H.
Results: The mean age of patients was 59 years (range: 30-89) and all were women. T1 tumors were 57.9% and N0 were 67.5%. Meanwhile, the tumors with nuclear grade 3 were 66.2% and high Ki-67 (> 30%) were 66.7%. Among the 228 tumors, 222 tumors (97.4%) revealed MSS, of which 6 (2.6%) revealed MSI and 2 (0.9%) were MSI-H. Among the MSI tumors, T and N factor were showed as follows: T1: 2 tumors, T2: 3 tumors, T3: 1 tumor, N0: 5 tumors and N1: 1 tumor. Of two MSI-H tumors, one showed T1N0 and another showed T2N0. The both of them showed nuclear grade 3, high Ki-67 (> 30%) and had common following instable markers: NR-21, BAT-26 and BAT-25.
Conclusions: Our results demonstrated that the frequency of MSI-H was 0.9% (2/228). MSI might not be useful as a biomarker for immune check point inhibitors. MSI should be combined with another biomarker such as tumor mutational burden in TNBC.
Citation Format: Kurata K, Kubo M, Mori H, Kawaji H, Motoyama Y, Kuroki L, Yamada M, Kaneshiro K, Kai M, Nakamura M. Microsatellite instability in triple negative breast cancers [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-06-11.
Collapse
Affiliation(s)
- K Kurata
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - M Kubo
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - H Mori
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - H Kawaji
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Y Motoyama
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - L Kuroki
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - M Yamada
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - K Kaneshiro
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - M Kai
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - M Nakamura
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| |
Collapse
|
17
|
Mori H, Kubo M, Kai M, Kurata K, Kawaji H, Kaneshiro K, Motoyama Y, Kuroki R, Yamada M, Nishimura R, Okido M, Oda Y, Nakamura M. Abstract P4-06-22: Transcription factor T-bet and PD-L1 expression in tumor microenvironment of triple-negative breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-06-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Many analyzes regarding immunotherapies using checkpoint blockade has made it clear that tumor infiltrating lymphocytes (TILs) plays an important role in treating cancers with high levels of somatic mutations such as triple-negative breast cancer (TNBC). We reported the relationship between TILs and PD-L1 expression, and revealed that high-TILs/positive-PD-L1 expression population in TNBC was associated with better prognosis (Oncotarget 2017). However, its molecular mechanism is still unclear. Meanwhile, T-box transcription factor 21 (T-bet) which regulates effecter T-cells activation is derived by stimulation of T-cell receptor and IL-12. Activated T-cells work as antitumor lymphocytes by enhancing the production of cytokines such as INFγ. We focused on T-bet and examined the function of activated T-cells.
Patients and Methods: This study included 242 patients with primary TNBC who underwent resection without neoadjuvant chemotherapy at our three hospitals between January 2004 and December 2014. The immunohistochemistry scoring for CD8 and T-bet expression on TILs was defined as ≥30 per 0.00625mm2. PD-L1 positivity was defined as ≥1% of tumor cells staining positive for PD-L1.
Results: Of the 242 TNBC, CD8 on TILs was expressed as positive in 127 (52.5%) tumors, T-bet on TILs was expressed as positive in 67 (27.7%) tumors, and PD-L1 expression on tumor cells was expressed as positive in 99 (40.9%) tumors. T-bet expression was significantly correlated with CD8 expression (P<0.0001) and PD-L1 expression (P=0.0004). There was no significant difference in recurrence free survival (RFS) and overall survival (OS) regardless of CD8 or PD-L1expression level. Meanwhile, the patients with T-bet-positive tumors had a longer OS, compared to those with T-bet-negative tumors (P = 0.13 in RFS and P = 0.047 in OS). The multivariate analysis revealed that T-bet expression on TILswas an independent and positive prognostic factor for OS(HR = 0.5, 95%CI 0.1-0.9, P = 0.035).
Conclusion: OS was significantly longer among patients with high T-bet expressing TNBC. These results may validate the significance of T-bet as a biomarker for various immunotherapies in TNBC.
Citation Format: Mori H, Kubo M, Kai M, Kurata K, Kawaji H, Kaneshiro K, Motoyama Y, Kuroki R, Yamada M, Nishimura R, Okido M, Oda Y, Nakamura M. Transcription factor T-bet and PD-L1 expression in tumor microenvironment of triple-negative breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-06-22.
Collapse
Affiliation(s)
- H Mori
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - M Kubo
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - M Kai
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - K Kurata
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - H Kawaji
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - K Kaneshiro
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - Y Motoyama
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - R Kuroki
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - M Yamada
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - R Nishimura
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - M Okido
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - Y Oda
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| | - M Nakamura
- Kyushu University, Fukuoka, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto, Japan; Breast Center, Hamanomachi Hospital, Fukuoka, Japan
| |
Collapse
|
18
|
Otomi Y, Otsuka H, Terazawa K, Yamanaka M, Obama Y, Arase M, Otomo M, Irahara S, Kubo M, Uyama N, Abe T, Harada M. The diagnostic ability of SPECT/CT fusion imaging for gastrointestinal bleeding: a retrospective study. BMC Gastroenterol 2018; 18:183. [PMID: 30526506 PMCID: PMC6288946 DOI: 10.1186/s12876-018-0915-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/29/2018] [Accepted: 11/28/2018] [Indexed: 01/22/2023] Open
Abstract
Background Blood loss from the gastrointestinal tract can be an acute and life-threatening event. For the treatment of gastrointestinal bleeding, it is important to accurately detect gastrointestinal bleeding and to localize the sites of bleeding. The purpose of this study was to retrospectively assess the capabilities of SPECT/CT in the diagnosis of gastrointestinal bleeding by a comparison with planar imaging alone as well as planar and SPECT. Methods We conducted a retrospective analysis of 20 patients (21 examinations) who underwent gastrointestinal bleeding scintigraphy in the past 7 years and in whom the bleeding site was identified by endoscopy or capsule endoscopy, or in whom no evidence of gastrointestinal bleeding was identified during the clinical course. Five patients (5 examinations) were diagnosed by planar imaging (planar group). Eight patients (9 examinations) were diagnosed by planar imaging and SPECT (planar + SPECT group). Seven patients (7 examinations) were diagnosed by planar imaging and SPECT/CT (planar + SPECT/CT group). We calculated the diagnostic ability of each method in detecting the presence of bleeding, as well as the ability of each method to identify the sites of bleeding. The sensitivity, specificity, and accuracy of the methods were compared. Results The diagnostic ability of the three imaging methods in detecting the presence of gastrointestinal bleeding was as follows. Planar imaging showed 100% sensitivity (3/3), 100% specificity (2/2), and 100% accuracy (5/5). Planar + SPECT imaging showed 85.7% sensitivity (6/7), 100% specificity (2/2), and 88.9% accuracy (8/9). Planar + SPECT/CT imaging showed 100% sensitivity (6/6), 100% specificity (1/1), and 100% accuracy (7/7). The diagnostic ability of the three modalities in detecting the site of bleeding was as follows: planar, 33.3% (1/3); planar + SPECT, 71.4% (5/7); and planar + SPECT/CT, 100% (6/6). Conclusions All 3 imaging methods showed good accuracy in detecting the presence of gastrointestinal bleeding. The addition of SPECT or SPECT/CT made the anatomical position of the uptake clear and contributed to the localization of the site of gastrointestinal bleeding. Planar + SPECT/CT imaging therefore showed the highest diagnostic ability for detecting the site of gastrointestinal bleeding.
Collapse
Affiliation(s)
- Yoichi Otomi
- Department of Radiology, Tokushima University Hospital, 2-50-1 Kuramoto-cho, Tokushima, Tokushima, 770-8503, Japan
| | - Hideki Otsuka
- Department of Radiology, Tokushima University Hospital, 2-50-1 Kuramoto-cho, Tokushima, Tokushima, 770-8503, Japan. .,Department of Medical Imaging/Nuclear Medicine, Institute of Biomedical Sciences, Tokushima University Graduate School, 2-50-1 Kuramoto-cho, Tokushima, 770-8503, Japan.
| | - Kaori Terazawa
- Department of Radiology, Tokushima University Hospital, 2-50-1 Kuramoto-cho, Tokushima, Tokushima, 770-8503, Japan
| | - Moriaki Yamanaka
- Department of Radiology, Tokushima University Hospital, 2-50-1 Kuramoto-cho, Tokushima, Tokushima, 770-8503, Japan
| | - Yuki Obama
- Department of Radiology, Tokushima University Hospital, 2-50-1 Kuramoto-cho, Tokushima, Tokushima, 770-8503, Japan
| | - Maki Arase
- Department of Radiology, Tokushima University Hospital, 2-50-1 Kuramoto-cho, Tokushima, Tokushima, 770-8503, Japan
| | - Maki Otomo
- Department of Radiology, Tokushima University Hospital, 2-50-1 Kuramoto-cho, Tokushima, Tokushima, 770-8503, Japan
| | - Saho Irahara
- Department of Radiology, Tokushima University Hospital, 2-50-1 Kuramoto-cho, Tokushima, Tokushima, 770-8503, Japan
| | - Michiko Kubo
- Department of Radiology, Tokushima University Hospital, 2-50-1 Kuramoto-cho, Tokushima, Tokushima, 770-8503, Japan
| | - Naoto Uyama
- Department of Radiology, Tokushima University Hospital, 2-50-1 Kuramoto-cho, Tokushima, Tokushima, 770-8503, Japan
| | - Takashi Abe
- Department of Radiology, Tokushima University Hospital, 2-50-1 Kuramoto-cho, Tokushima, Tokushima, 770-8503, Japan
| | - Masafumi Harada
- Department of Radiology, Tokushima University Hospital, 2-50-1 Kuramoto-cho, Tokushima, Tokushima, 770-8503, Japan
| |
Collapse
|
19
|
Umekawa T, Maki S, Kubo M, Tanaka H, Nii M, Tanaka K, Osato K, Kamimoto Y, Tamaru S, Ogura T, Nishimura Y, Kodera M, Minamide C, Nishikawa M, Endoh M, Kimura T, Kotani T, Nakamura M, Sekizawa A, Ikeda T. TADAFER II: Tadalafil treatment for fetal growth restriction - a study protocol for a multicenter randomised controlled phase II trial. BMJ Open 2018; 8:e020948. [PMID: 30381311 PMCID: PMC6224767 DOI: 10.1136/bmjopen-2017-020948] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
INTRODUCTION There is no proven therapy to reverse or ameliorate fetal growth restriction (FGR). Sildenafil, a selective phosphodiesterase 5 (PDE5) inhibitor, has been reported to potentially play a therapeutic role in FGR, but this has not been established. Tadalafil is also a selective PDE5 inhibitor. We have demonstrated the efficacy of tadalafil against FGR along with short-term outcomes and the feasibility of tadalafil treatment. Based on the hypothesis that tadalafil will safely increase the likelihood of increased fetal growth in FGR, we designed this phase II study to prospectively evaluate the efficacy and safety of tadalafil against FGR. METHODS AND ANALYSIS This study is a multicentre, randomised controlled phase II trial. A total of 140 fetuses with FGR will be enrolled from medical centres in Japan. Fetuses will be randomised to receive either the conventional management for FGR or a once-daily treatment with 20 mg of tadalafil along with the conventional management until delivery. The primary endpoint is fetal growth velocity from the first day of the protocol-defined treatment to birth (g/day). To minimise bias in terms of fetal baseline conditions and timing of delivery, a fetal indication for delivery was established in this study. The investigator will evaluate fetal baseline conditions at enrolment and will decide the timing of delivery based on this fetal indication. Infants will be followed up for development until 1.5 years of age. ETHICS AND DISSEMINATION This study was approved by the Institutional Review Board of Mie University Hospital and each participating institution. Our findings will be widely disseminated through peer-reviewed publications. TRIAL REGISTRATION NUMBER UMIN000023778.
Collapse
Affiliation(s)
- Takashi Umekawa
- Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Tsu, Japan
| | - Shintaro Maki
- Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Tsu, Japan
| | - Michiko Kubo
- Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Tsu, Japan
| | - Hiroaki Tanaka
- Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Tsu, Japan
| | - Masafumi Nii
- Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Tsu, Japan
| | - Kayo Tanaka
- Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Tsu, Japan
| | - Kazuhiro Osato
- Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Tsu, Japan
| | - Yuki Kamimoto
- Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Tsu, Japan
| | - Satoshi Tamaru
- Clinical Research Support Center, Mie University Hospital, Tsu, Japan
| | - Toru Ogura
- Clinical Research Support Center, Mie University Hospital, Tsu, Japan
| | - Yuki Nishimura
- Clinical Research Support Center, Mie University Hospital, Tsu, Japan
| | - Mayumi Kodera
- Clinical Research Support Center, Mie University Hospital, Tsu, Japan
| | - Chisato Minamide
- Clinical Research Support Center, Mie University Hospital, Tsu, Japan
| | | | - Masayuki Endoh
- Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Japan
| | - Tadashi Kimura
- Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Japan
| | - Tomomi Kotani
- Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Masamitsu Nakamura
- Department of Obstetrics and Gynecology, Showa University Graduate School of Medicine, Tokyo, Japan
| | - Akihiko Sekizawa
- Department of Obstetrics and Gynecology, Showa University Graduate School of Medicine, Tokyo, Japan
| | - Tomoaki Ikeda
- Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Tsu, Japan
| |
Collapse
|
20
|
Innocenti F, Jiang C, Sibley A, Denning S, Etheridge A, Watson D, Niedzwiecki D, Hatch A, Hurwitz H, Nixon A, Furukawa Y, Kubo M, Crona D, Kindler H, McLeod H, Ratain M, Owzar K. A genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy303.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
21
|
Kubo M, Tabaru K, Shoji H, Harashima T. Speech perception of preschool children in real-life classroom noise. Int J Psychophysiol 2018. [DOI: 10.1016/j.ijpsycho.2018.07.302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
22
|
Nii M, Kondo E, Maki S, Kubo M, Yoshida K, Zhang L, Kobayashi Y, Tabata T, Ikeda T. Safety and Efficacy of Laparoscopic Oophorocystectomy for Ovarian Dermoid Cyst Associated With Autoimmune Hemolytic Anemia. Gynecol Minim Invasive Ther 2018; 7:27-30. [PMID: 30254931 PMCID: PMC6135149 DOI: 10.4103/gmit.gmit_9_17] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Ovarian dermoid cysts (ODCs) are the most common benign tumors in young women, but autoimmune hemolytic anemia (AIHA) induced by ODC is rare. We report the first case of ODC-associated AIHA with improvement after laparoscopic oophorocystectomy. An 18-year-old nulliparous woman was diagnosed with a left ODC that was 7 cm in diameter. Preoperative blood tests showed macrocytic anemia, reticulocytosis, high serum lactate dehydrogenase activity, hyperbilirubinemia, and low haptoglobin. Direct and indirect Coombs tests were positive. We diagnosed AIHA. Prednisolone therapy did not result in improvement, so it seemed that AIHA was being induced by the ODC. After laparoscopic oophorocystectomy, the patient's condition improved without blood transfusion. Resection of ODC should be performed first for ODC-associated AIHA; laparoscopic surgery may be superior to laparotomy from the standpoint of hemorrhage given the underlying anemia.
Collapse
Affiliation(s)
- Masafumi Nii
- Department of Obstetrics and Gynecology, Mie University School of Medicine, Tsu, Mie, Japan
| | - Eiji Kondo
- Department of Obstetrics and Gynecology, Mie University School of Medicine, Tsu, Mie, Japan
| | - Shintaro Maki
- Department of Obstetrics and Gynecology, Mie University School of Medicine, Tsu, Mie, Japan
| | - Michiko Kubo
- Department of Obstetrics and Gynecology, Mie University School of Medicine, Tsu, Mie, Japan
| | - Kenta Yoshida
- Department of Obstetrics and Gynecology, Mie University School of Medicine, Tsu, Mie, Japan
| | - Lingyun Zhang
- Department of Obstetrics and Gynecology, Mie University School of Medicine, Tsu, Mie, Japan
| | - Yoshiyuki Kobayashi
- Department of Obstetrics and Gynecology, Mie University School of Medicine, Tsu, Mie, Japan
| | - Tsutomu Tabata
- Department of Obstetrics and Gynecology, Mie University School of Medicine, Tsu, Mie, Japan
| | - Tomoaki Ikeda
- Department of Obstetrics and Gynecology, Mie University School of Medicine, Tsu, Mie, Japan
| |
Collapse
|
23
|
Tanaka N, Kunihiro Y, Kubo M, Kawano R, Oishi K, Ueda K, Gondo T. HRCT findings of collagen vascular disease-related interstitial pneumonia (CVD-IP): a comparative study among individual underlying diseases. Clin Radiol 2018; 73:833.e1-833.e10. [DOI: 10.1016/j.crad.2018.04.017] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2017] [Accepted: 04/23/2018] [Indexed: 01/14/2023]
|
24
|
Tanaka H, Maki S, Kubo M, Yuasa H, Umekawa T, Ikeda T. Treatment using tadalafil for dichorionic diamniotic twin pregnancy with fetal growth restriction. CLIN EXP OBSTET GYN 2018. [DOI: 10.12891/ceog4340.2018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
25
|
Shimanoe C, Hachiya T, Hara M, Nishida Y, Tanaka K, Sutoh Y, Shimizu A, Hishida A, Kawai S, Okada R, Tamura T, Matsuo K, Ito H, Ozaki E, Matsui D, Ibusuki R, Shimoshikiryo I, Takashima N, Kadota A, Arisawa K, Uemura H, Suzuki S, Watanabe M, Kuriki K, Endoh K, Mikami H, Nakamura Y, Momozawa Y, Kubo M, Nakatochi M, Naito M, Wakai K. A genome-wide association study of coping behaviors suggests FBXO45
is associated with emotional expression. Genes, Brain and Behavior 2018; 18:e12481. [DOI: 10.1111/gbb.12481] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/23/2017] [Revised: 03/15/2018] [Accepted: 04/11/2018] [Indexed: 12/20/2022]
Affiliation(s)
- C. Shimanoe
- Department of Preventive Medicine, Faculty of Medicine; Saga University; Saga Japan
| | - T. Hachiya
- Division of Biomedical Information Analysis, Iwate Tohoku Medical Megabank Organization; Disaster Reconstruction Center, Iwate Medical University; Iwate Japan
| | - M. Hara
- Department of Preventive Medicine, Faculty of Medicine; Saga University; Saga Japan
| | - Y. Nishida
- Department of Preventive Medicine, Faculty of Medicine; Saga University; Saga Japan
| | - K. Tanaka
- Department of Preventive Medicine, Faculty of Medicine; Saga University; Saga Japan
| | - Y. Sutoh
- Division of Biomedical Information Analysis, Iwate Tohoku Medical Megabank Organization; Disaster Reconstruction Center, Iwate Medical University; Iwate Japan
| | - A. Shimizu
- Division of Biomedical Information Analysis, Iwate Tohoku Medical Megabank Organization; Disaster Reconstruction Center, Iwate Medical University; Iwate Japan
| | - A. Hishida
- Department of Preventive Medicine; Nagoya University Graduate School of Medicine; Nagoya Japan
| | - S. Kawai
- Department of Preventive Medicine; Nagoya University Graduate School of Medicine; Nagoya Japan
| | - R. Okada
- Department of Preventive Medicine; Nagoya University Graduate School of Medicine; Nagoya Japan
| | - T. Tamura
- Department of Preventive Medicine; Nagoya University Graduate School of Medicine; Nagoya Japan
| | - K. Matsuo
- Division of Molecular and Clinical Epidemiology; Aichi Cancer Center Research Institute; Nagoya Japan
| | - H. Ito
- Division of Molecular and Clinical Epidemiology; Aichi Cancer Center Research Institute; Nagoya Japan
| | - E. Ozaki
- Department of Epidemiology for Community Health and Medicine; Kyoto Prefectural University of Medicine; Kyoto Japan
| | - D. Matsui
- Department of Epidemiology for Community Health and Medicine; Kyoto Prefectural University of Medicine; Kyoto Japan
| | - R. Ibusuki
- Department of International Island and Community Medicine; Kagoshima University Graduate School of Medical and Dental Sciences; Kagoshima Japan
| | - I. Shimoshikiryo
- Department of International Island and Community Medicine; Kagoshima University Graduate School of Medical and Dental Sciences; Kagoshima Japan
| | - N. Takashima
- Department of Public Health; Shiga University of Medical Science; Otsu Japan
| | - A. Kadota
- Department of Public Health; Shiga University of Medical Science; Otsu Japan
- Center for Epidemiologic Research in Asia; Shiga University of Medical Science; Otsu Japan
| | - K. Arisawa
- Department of Preventive Medicine; Institute of Biomedical Sciences, Tokushima University Graduate School; Tokushima Japan
| | - H. Uemura
- Department of Preventive Medicine; Institute of Biomedical Sciences, Tokushima University Graduate School; Tokushima Japan
| | - S. Suzuki
- Department of Public Health; Nagoya City University Graduate School of Medical Sciences; Nagoya Japan
| | - M. Watanabe
- Department of Public Health; Nagoya City University Graduate School of Medical Sciences; Nagoya Japan
| | - K. Kuriki
- Laboratory of Public Health, Division of Nutritional Sciences, School of Food and Nutritional Sciences; University of Shizuoka; Shizuoka Japan
| | - K. Endoh
- Laboratory of Public Health, Division of Nutritional Sciences, School of Food and Nutritional Sciences; University of Shizuoka; Shizuoka Japan
| | - H. Mikami
- Division of Cancer Prevention and Epidemiology; Chiba Cancer Center; Chiba Japan
| | - Y. Nakamura
- Division of Cancer Prevention and Epidemiology; Chiba Cancer Center; Chiba Japan
| | - Y. Momozawa
- Laboratory for Genotyping Development; RIKEN Center for Integrative Medical Sciences; Yokohama Japan
| | - M. Kubo
- RIKEN Center for Integrative Medical Sciences; Yokohama Japan
| | - M. Nakatochi
- Statistical Analysis Section; Center for Advanced Medicine and Clinical Research, Nagoya University Hospital; Nagoya Japan
| | - M. Naito
- Department of Maxillofacial Functional Development; Graduate School of Biomedical and Health Sciences, Hiroshima University; Hiroshima Japan
| | - K. Wakai
- Department of Preventive Medicine; Nagoya University Graduate School of Medicine; Nagoya Japan
| |
Collapse
|
26
|
Shukunami K, Kurokawa T, Kubo M, Kaneshima M, Kamitani N, Kotsuji F. Hypersensitivity Reaction to Carboplatin during Treatment for Ovarian Cancer: Successful Resolution by Replacement with Cisplatin. Tumori 2018; 85:297-8. [PMID: 10587037 DOI: 10.1177/030089169908500418] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Development of hypersensitivity reactions to carboplatin (CP) during cancer treatment makes optimal chemotherapy difficult to achieve. Many approaches have previously been used following the development of reactions to CP. We report on a patient with ovarian cancer who developed a hypersensitivity reaction to CP. The patient was successfully treated following replacement of carboplatin with cisplatin.
Collapse
Affiliation(s)
- K Shukunami
- Department of Obstetrics and Gynecology, Fukui Medical University, Yoshida-Gun, Japan
| | | | | | | | | | | |
Collapse
|
27
|
Okuno M, Ayabe T, Yokota I, Musha I, Shiga K, Kikuchi T, Kikuchi N, Ohtake A, Nakamura A, Nakabayashi K, Okamura K, Momozawa Y, Kubo M, Suzuki J, Urakami T, Kawamura T, Amemiya S, Ogata T, Sugihara S, Fukami M. Protein-altering variants of PTPN2 in childhood-onset Type 1A diabetes. Diabet Med 2018; 35:376-380. [PMID: 29247561 DOI: 10.1111/dme.13566] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 12/12/2017] [Indexed: 12/31/2022]
Abstract
AIM To examine the contribution of PTPN2 coding variants to the risk of childhood-onset Type 1A diabetes. METHODS PTPN2 mutation analysis was carried out for 169 unrelated Japanese people with childhood-onset Type 1A diabetes. We searched for coding variants that were absent or extremely rare in the general population and were scored as damaging by multiple in silico programs. We performed mRNA analysis and three-dimensional structural prediction of the detected variants, when possible. We also examined possible physical links between these variants and previously reported risk SNPs as well as clinical information from variant-positive children. RESULTS One frameshift variant (p.Q286Yfs*24) and two probably damaging missense substitutions (p.C232W and p.R350Q) were identified in one child each. Of these, p.Q286Yfs*24 and p.C232W were hitherto unreported, while p.R350Q accounted for 2/121,122 alleles of the exome datasets. The p.Q286Yfs*24 variant did not encode stable mRNA, and p.C232W appeared to affect the structure of the tyrosine-protein phosphatase domain. The three variants were physically unrelated to known risk SNPs. The variant-positive children manifested Type 1A diabetes without additional clinical features and invariably carried risk human leukocyte antigen alleles. CONCLUSIONS The results provide the first indication that PTPN2 variants contribute to the risk of Type 1A diabetes, independently of known risk SNPs. PTPN2 coding variants possibly induce non-specific Type 1A diabetes phenotypes in individuals with human leukocyte antigen-mediated disease susceptibility. Our findings warrant further validation.
Collapse
Affiliation(s)
- M Okuno
- Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo
- Department of Paediatrics and Child Health, Nihon University School of Medicine, Tokyo
| | - T Ayabe
- Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo
| | - I Yokota
- Department of Paediatrics, Division of Paediatric Endocrinology and Metabolism, Shikoku Medical Centre for Children and Adults, Kagawa
| | - I Musha
- Department of Paediatrics, Saitama Medical University, Faculty of Medicine, Saitama
| | - K Shiga
- Department of Paediatrics, Children's Medical Centre, Yokohama City University Medical Centre, Yokohama
| | - T Kikuchi
- Department of Paediatrics, Saitama Medical University, Faculty of Medicine, Saitama
| | - N Kikuchi
- Department of Paediatrics, Yokohama City Minato Red Cross Hospital, Yokohama
| | - A Ohtake
- Department of Paediatrics, Saitama Medical University, Faculty of Medicine, Saitama
| | - A Nakamura
- Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo
| | - K Nakabayashi
- Department of Maternal-Fetal Biology, National Research Institute for Child Health and Development, Tokyo
| | - K Okamura
- Systems BioMedicine, National Research Institute for Child Health and Development, Tokyo
| | - Y Momozawa
- Laboratory for Genotyping Development, Riken Centre for Integrative Medical Sciences, Kanagawa
| | - M Kubo
- Laboratory for Genotyping Development, Riken Centre for Integrative Medical Sciences, Kanagawa
| | - J Suzuki
- Department of Paediatrics and Child Health, Nihon University School of Medicine, Tokyo
| | - T Urakami
- Department of Paediatrics and Child Health, Nihon University School of Medicine, Tokyo
| | - T Kawamura
- Department of Paediatrics, Osaka City University School of Medicine, Osaka
| | - S Amemiya
- Department of Paediatrics, Saitama Medical University, Faculty of Medicine, Saitama
| | - T Ogata
- Department of Paediatrics, Hamamatsu University School of Medicine, Hamamatsu
| | - S Sugihara
- Department of Paediatrics, Tokyo Women's Medical University Medical Centre East, Tokyo, Japan
| | - M Fukami
- Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo
| |
Collapse
|
28
|
Ikeda M, Takahashi A, Kamatani Y, Okahisa Y, Kunugi H, Mori N, Sasaki T, Ohmori T, Okamoto Y, Kawasaki H, Shimodera S, Kato T, Yoneda H, Yoshimura R, Iyo M, Matsuda K, Akiyama M, Ashikawa K, Kashiwase K, Tokunaga K, Kondo K, Saito T, Shimasaki A, Kawase K, Kitajima T, Matsuo K, Itokawa M, Someya T, Inada T, Hashimoto R, Inoue T, Akiyama K, Tanii H, Arai H, Kanba S, Ozaki N, Kusumi I, Yoshikawa T, Kubo M, Iwata N. A genome-wide association study identifies two novel susceptibility loci and trans population polygenicity associated with bipolar disorder. Mol Psychiatry 2018; 23:639-647. [PMID: 28115744 PMCID: PMC5822448 DOI: 10.1038/mp.2016.259] [Citation(s) in RCA: 114] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/13/2016] [Revised: 11/29/2016] [Accepted: 12/13/2016] [Indexed: 11/09/2022]
Abstract
Genome-wide association studies (GWASs) have identified several susceptibility loci for bipolar disorder (BD) and shown that the genetic architecture of BD can be explained by polygenicity, with numerous variants contributing to BD. In the present GWAS (Phase I/II), which included 2964 BD and 61 887 control subjects from the Japanese population, we detected a novel susceptibility locus at 11q12.2 (rs28456, P=6.4 × 10-9), a region known to contain regulatory genes for plasma lipid levels (FADS1/2/3). A subsequent meta-analysis of Phase I/II and the Psychiatric GWAS Consortium for BD (PGC-BD) identified another novel BD gene, NFIX (Pbest=5.8 × 10-10), and supported three regions previously implicated in BD susceptibility: MAD1L1 (Pbest=1.9 × 10-9), TRANK1 (Pbest=2.1 × 10-9) and ODZ4 (Pbest=3.3 × 10-9). Polygenicity of BD within Japanese and trans-European-Japanese populations was assessed with risk profile score analysis. We detected higher scores in BD cases both within (Phase I/II) and across populations (Phase I/II and PGC-BD). These were defined by (1) Phase II as discovery and Phase I as target, or vice versa (for 'within Japanese comparisons', Pbest~10-29, R2~2%), and (2) European PGC-BD as discovery and Japanese BD (Phase I/II) as target (for 'trans-European-Japanese comparison,' Pbest~10-13, R2~0.27%). This 'trans population' effect was supported by estimation of the genetic correlation using the effect size based on each population (liability estimates~0.7). These results indicate that (1) two novel and three previously implicated loci are significantly associated with BD and that (2) BD 'risk' effect are shared between Japanese and European populations.
Collapse
Affiliation(s)
- M Ikeda
- Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan
| | - A Takahashi
- Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
- Laboratory for Omics Informatics, Omics Research Center, National Cerebral and Cardiovascular Center, Osaka, Japan
| | - Y Kamatani
- Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Y Okahisa
- Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - H Kunugi
- Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan
| | - N Mori
- Department of Psychiatry and Neurology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - T Sasaki
- Laboratory of Health Education, Graduate School of Education, the University of Tokyo, Tokyo, Japan
| | - T Ohmori
- Department of Psychiatry, Course of Integrated Brain Sciences, Medical Informatics, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan
| | - Y Okamoto
- Department of Psychiatry and Neurosciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - H Kawasaki
- Department of Psychiatry, Fukuoka University, Faculty of Medicine, Fukuoka, Japan
| | - S Shimodera
- Department of Neuropsychiatry, Kochi Medical School, Kochi University, Nankoku, Japan
| | - T Kato
- Laboratory for Molecular Dynamics of Mental Disorders, RIKEN Brain Science Institute, Wako, Japan
| | - H Yoneda
- Department of Neuropsychiatry, Osaka Medical College, Takatsuki, Japan
| | - R Yoshimura
- Department of Psychiatry, University of Occupational and Environmental Health, Kitakyusyu, Japan
| | - M Iyo
- Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan
| | - K Matsuda
- Laboratory of Clinical Sequence, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan
| | - M Akiyama
- Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - K Ashikawa
- Laboratory for Genotyping Development, Center for Integrative Medical Sciences, RIKEN, Japan
| | - K Kashiwase
- Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan
| | - K Tokunaga
- Department of Human Genetics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - K Kondo
- Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan
| | - T Saito
- Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan
| | - A Shimasaki
- Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan
| | - K Kawase
- Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan
| | - T Kitajima
- Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan
| | - K Matsuo
- Division of Neuropsychiatry, Department of Neuroscience, Yamaguchi University Graduate School of Medicine, Ube, Japan
| | - M Itokawa
- Center for Medical Cooperation, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
| | - T Someya
- Department of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - T Inada
- Department of Psychiatry, Nagoya University, Graduate School of Medicine, Nagoya, Japan
| | - R Hashimoto
- Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, Osaka University, Suita, Japan
| | - T Inoue
- Department of Psychiatry, Tokyo Medical University, Tokyo, Japan
| | - K Akiyama
- Department of Biological Psychiatry and Neuroscience, Dokkyo Medical University School of Medicine, Mibu, Japan
| | - H Tanii
- Department of Neuropsychiatry, Mie University, Graduate School of Medicine, Tsu, Japan
| | - H Arai
- Department of Psychiatry and Behavioral Sciences, Juntendo Graduate School of Medicine, Tokyo, Japan
| | - S Kanba
- Department of Neuropsychiatry, Kyushu University, Graduate School of Medical Sciences, Fukuoka, Japan
| | - N Ozaki
- Department of Psychiatry, Nagoya University, Graduate School of Medicine, Nagoya, Japan
| | - I Kusumi
- Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| | - T Yoshikawa
- Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, Wako, Japan
| | - M Kubo
- RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - N Iwata
- Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan
| |
Collapse
|
29
|
Tanaka K, Tanaka H, Maki S, Kubo M, Nii M, Magawa S, Hatano F, Tsuji M, Osato K, Kamimoto Y, Umekawa T, Ikeda T. Cardiac function and tadalafil used for treating fetal growth restriction in pregnant women without cardiovascular disease. J Matern Fetal Neonatal Med 2018; 32:2460-2462. [PMID: 29415591 DOI: 10.1080/14767058.2018.1438401] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
BACKGROUND The aim of the present study was to evaluate tadalafil for the treatment of fetal growth restriction (FGR) and the cardiac function in pregnant women without cardiovascular disease who used tadalafil for this reason. MATERIALS AND METHODS We examined nine pregnant women without cardiovascular disease who were using tadalafil to treat FGR. Maternal heart rate, systolic blood pressure (BP), and echocardiographic findings were assessed before and after tadalafil use. RESULTS Diastolic BP was lower after compared to that before using tadalafil, but the difference was not significant. Echocardiographic findings were not significantly different before and after tadalafil use. CONCLUSIONS Tadalafil did not adversely affect pregnant women without cardiovascular disease and was considered acceptable for use since it did not affect the mother's cardiac function.
Collapse
Affiliation(s)
- Kayo Tanaka
- a Department of Obstetrics and Gynecology , Mie University School of Medicine , Mie , Japan
| | - Hiroaki Tanaka
- a Department of Obstetrics and Gynecology , Mie University School of Medicine , Mie , Japan
| | - Shintaro Maki
- a Department of Obstetrics and Gynecology , Mie University School of Medicine , Mie , Japan
| | - Michiko Kubo
- a Department of Obstetrics and Gynecology , Mie University School of Medicine , Mie , Japan
| | - Masafumi Nii
- a Department of Obstetrics and Gynecology , Mie University School of Medicine , Mie , Japan
| | - Shoichi Magawa
- a Department of Obstetrics and Gynecology , Mie University School of Medicine , Mie , Japan
| | - Fumi Hatano
- a Department of Obstetrics and Gynecology , Mie University School of Medicine , Mie , Japan
| | - Makoto Tsuji
- a Department of Obstetrics and Gynecology , Mie University School of Medicine , Mie , Japan
| | - Kazuhiro Osato
- a Department of Obstetrics and Gynecology , Mie University School of Medicine , Mie , Japan
| | - Yuki Kamimoto
- a Department of Obstetrics and Gynecology , Mie University School of Medicine , Mie , Japan
| | - Takashi Umekawa
- a Department of Obstetrics and Gynecology , Mie University School of Medicine , Mie , Japan
| | - Tomoaki Ikeda
- a Department of Obstetrics and Gynecology , Mie University School of Medicine , Mie , Japan
| |
Collapse
|
30
|
Cairns J, Ingle JN, Shepherd LE, Kubo M, Goetz MP, Weinshilboum RM, Kalari KR, Wang L. Abstract P5-07-01: LncRNA MIR2052HG regulates ERα level and endocrine resistance through LMTK3 by recruiting early growth response protein 1. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-07-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: A GWAS for the MA.27 aromatase inhibitors (AIs) adjuvant trial (4,406 controls and 252 cases) identified variant (V) SNPs in a long noncoding (lnc) RNA, MIR2052HG, that were associated with longer breast cancer free interval (HR= 0.37, P= 2.15E-07). V SNPs (MAF= 0.32 to 0.42) were associated with lower MIR2052HG and ERα expression in the presence of AIs. MIR2052HG maintained ERα both by promoting AKT/FOXO3-mediated ESR1 transcription and by limiting ubiquitin-mediated ERα degradation. (Cancer Res 76:7012-23, 2016). Our goal was to further elucidate MIR2052HG's mechanism of action.
METHODS: RNA-Binding Protein Immunoprecipitation (RBPI) assays were performed to demonstrate that the transcription factor, early growth response protein 1 (EGR1), worked together with MIR2052HG to regulate lemur tyrosine kinase-3 (LMTK3) transcription in MCF7/AC1 and CAMA-1 cells. The location of EGR1 on the LMTK3 gene locus was mapped using chromatin immunoprecipitation (ChIP) assays. The co-localization of MIR2052HG RNA and the LMTK3 gene locus was determined using RNA-DNA dual fluorescent in situ hybridization (FISH). SNP effects were evaluated using a panel of human lymphoblastoid cell lines.
RESULTS: TCGA analysis revealed LMTK3 and MIR2052HG expression were highly correlated in ERα-positive breast cancer patients. We found that the MIR2052HG transcript was located in the LMTK3 gene locus by RNA-DNA FISH. Among all of the 12 potential LMTK3 transcription factors identified in the Encode database that were examined by RBPI, only EGR1 showed an interaction with MIR2052HG. CHIP assays confirmed EGR1 binding to the two putative EGR1 binding sites in LMTK3 gene.Depletion of MIR2052HG reduced the binding of EGR1 to the LMTK3 promoter and decreased LMTK3 expression, suggesting that it might function as a scaffold. Mechanistically, decreased LMTK3 levels further increased protein kinase C (PKC) activity and downstream AKT activity, leading to reduced ESR1 mRNA levels via increased pFOXO3. At the protein level, in MIR2052HG depleted cells, increased PKC activity increased the phosphorylation of MEK, ERK, and RSK1, leading to increased ERα phosphorylation at Ser167 and increased ERα degradation. Conversely, overexpression of LMTK3 in MIR2052HG depleted cells reversed these phenotypes. MIR2052HG regulated LMTK3 and ERα expression in a SNP- dependent fashion: the MIR2052HG V SNP, relative to wild-type (WT) genotype, increased LMTK3/ERα expression in response to androstenedione due to increased binding between EGR1 and the LMTK3 promoter in LCLs. However, AI treatment reduced this binding in MIR2052HG variant cells but increased binding in WT cells, resulting in decreased LMTK3/ERα in V cells and increased expression in WT cells.
CONCLUSIONS: Our findings support a model in which the protective MIR2052HG variant genotype regulates LMTK3 via MIR2052HG/EGR1, and LMTK3 regulates ERα stability via the PKC/MEK/ERK/RSK1 axis. This regulation may explain the effect of the MIR2052HG variant genotype on cell proliferation and response to AIs in MA.27. These findings provide new insight into the mechanism of action of MIR2052HG and suggest that LMTK3 may be a new therapeutic target in ERα-positive breast cancer patients treated with AIs.
Citation Format: Cairns J, Ingle JN, Shepherd LE, Kubo M, Goetz MP, Weinshilboum RM, Kalari KR, Wang L. LncRNA MIR2052HG regulates ERα level and endocrine resistance through LMTK3 by recruiting early growth response protein 1 [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-07-01.
Collapse
Affiliation(s)
- J Cairns
- Mayo Clinic, Rochester, MN; Canadian Cancer Trials Group, Kingston, ON, Canada; Riken Center for Integrative Medical Science, Yokohama, Japan
| | - JN Ingle
- Mayo Clinic, Rochester, MN; Canadian Cancer Trials Group, Kingston, ON, Canada; Riken Center for Integrative Medical Science, Yokohama, Japan
| | - LE Shepherd
- Mayo Clinic, Rochester, MN; Canadian Cancer Trials Group, Kingston, ON, Canada; Riken Center for Integrative Medical Science, Yokohama, Japan
| | - M Kubo
- Mayo Clinic, Rochester, MN; Canadian Cancer Trials Group, Kingston, ON, Canada; Riken Center for Integrative Medical Science, Yokohama, Japan
| | - MP Goetz
- Mayo Clinic, Rochester, MN; Canadian Cancer Trials Group, Kingston, ON, Canada; Riken Center for Integrative Medical Science, Yokohama, Japan
| | - RM Weinshilboum
- Mayo Clinic, Rochester, MN; Canadian Cancer Trials Group, Kingston, ON, Canada; Riken Center for Integrative Medical Science, Yokohama, Japan
| | - KR Kalari
- Mayo Clinic, Rochester, MN; Canadian Cancer Trials Group, Kingston, ON, Canada; Riken Center for Integrative Medical Science, Yokohama, Japan
| | - L Wang
- Mayo Clinic, Rochester, MN; Canadian Cancer Trials Group, Kingston, ON, Canada; Riken Center for Integrative Medical Science, Yokohama, Japan
| |
Collapse
|
31
|
Yoshikawa K, Umekawa T, Maki S, Kubo M, Nii M, Tanaka K, Tanaka H, Osato K, Kamimoto Y, Kondo E, Ikemura K, Okuda M, Katayama K, Miyoshi T, Hosoda H, Ma N, Yoshida T, Ikeda T. Tadalafil Improves L-NG-Nitroarginine Methyl Ester-Induced Preeclampsia With Fetal Growth Restriction-Like Symptoms in Pregnant Mice. Am J Hypertens 2017; 31:89-96. [PMID: 28992178 DOI: 10.1093/ajh/hpx130] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2017] [Accepted: 07/11/2017] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND We investigated the efficacy and mechanisms of tadalafil, a selective phosphodiesterase 5 inhibitor, in treating preeclampsia (PE) with fetal growth restriction (FGR) using L-NG-nitroarginine methyl ester (L-NAME)-induced PE with FGR in pregnant mice as our experimental model. METHODS C57BL/6 mice were divided into 2 groups 11 days postcoitum (d.p.c.). A control group of dams (C dam) received 0.5% carboxymethylcellulose (CMC). A L-NAME-treated group received 1 mg/ml L-NAME dissolved in CMC. The L-NAME-treated dams were divided into 2 subgroups 13 d.p.c. One subgroup continued to receive L-NAME (L dams). The other subgroup received L-NAME with 0.08 mg/ml tadalafil suspended in CMC (TL dams). Maternal systolic blood pressure (SBP) and proteinuria were assessed 16 d.p.c. Fetal weight was recorded, and placentas and maternal kidneys were collected 17 d.p.c. RESULTS Maternal SBP, proteinuria, and fetal weight were improved for TL dams compared to L dams. The placental concentration of placental growth factor (PlGF) was higher for TL dams than for the C and L dams. The placental maternal blood sinuses of L dams were narrower than those of C dams, but those of TL dams improved to a similar width as C dams. Glomerular oxidative stress was ameliorated in TL dams compared to L dams. CONCLUSIONS Tadalafil dilates the placental maternal blood sinuses, which leads to increase PlGF production, and contributes to facilitate fetal growth and improve maternal SBP. Moreover, tadalafil ameliorates glomerular damage by reducing oxidative stress. These results suggest that tadalafil is a candidate for treatment of PE with FGR.
Collapse
Affiliation(s)
- Kento Yoshikawa
- Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Japan
| | - Takashi Umekawa
- Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Japan
| | - Shintaro Maki
- Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Japan
| | - Michiko Kubo
- Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Japan
| | - Masafumi Nii
- Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Japan
| | - Kayo Tanaka
- Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Japan
| | - Hiroaki Tanaka
- Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Japan
| | - Kazuhiro Osato
- Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Japan
| | - Yuki Kamimoto
- Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Japan
| | - Eiji Kondo
- Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Japan
| | - Kenji Ikemura
- Department of Pharmacy, Mie University Hospital, Japan
| | | | - Kan Katayama
- Department of Cardiology and Nephrology, Cardiology and Nephrology, Mie University Graduate School of Medicine, Japan
| | - Takekazu Miyoshi
- Department of Perinatology and Gynecology, National Cerebral and Cardiovascular Center, Japan
| | - Hiroshi Hosoda
- Department of Regenerative Medicine and Tissue Engineering, National Cerebral and Cardiovascular Center, Japan
| | - Ning Ma
- Faculty of Health Science, Suzuka University of Medical Science, Japan
| | - Toshimichi Yoshida
- Department of Pathology and Matrix Biology, Pathology and Matrix Biology, Mie University Graduate School of Medicine, Japan
| | - Tomoaki Ikeda
- Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Japan
| |
Collapse
|
32
|
Iwaki H, Kannnou M, Kubo M, Miyaue N, Tada S, Rina A, Tsujii T, Yabe H, Nishikawa N, Nagai M, Nomoto M. The association between Parkinson's disease and the serum levels of nutritional factors: A cross-sectional study with patient and spouse pairs. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.1004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
33
|
Furui E, Itabashi R, Yazawa Y, Kubo M, Horie Y. The novel ultrasound doppler machine for microembolus detection from the cervical arteries. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
34
|
Relling MV, Krauss RM, Roden DM, Klein TE, Fowler DM, Terada N, Lin L, Riel-Mehan M, Do TP, Kubo M, Yee SW, Johnson GT, Giacomini KM. New Pharmacogenomics Research Network: An Open Community Catalyzing Research and Translation in Precision Medicine. Clin Pharmacol Ther 2017; 102:897-902. [PMID: 28795399 DOI: 10.1002/cpt.755] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2017] [Revised: 05/17/2017] [Accepted: 05/21/2017] [Indexed: 12/25/2022]
Abstract
The goal of pharmacogenomics research is to discover genetic polymorphisms that underlie variation in drug response. Increasingly, pharmacogenomics research involves large numbers of patients and the application of new technologies and methodologies to enable discovery. The Pharmacogenomics Research Network (PGRN) has become a community-driven network of investigators spanning scientific and clinical disciplines. Here, we highlight the activities and types of resources that enable PGRN members to enhance and drive basic and translational research in pharmacogenomics.
Collapse
Affiliation(s)
- M V Relling
- Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
| | - R M Krauss
- Children's Hospital Oakland Research Institute, Oakland, California, USA
| | - D M Roden
- Vanderbilt University Medical Center, Nashville, Tennessee, USA
| | - T E Klein
- Department of Biomedical Data Science, Stanford University, Palo Alto, California, USA
| | - D M Fowler
- Department of Genome Sciences, University of Washington, Seattle, Washington, USA.,Department of Bioengineering, University of Washington, Seattle, Washington, USA
| | - N Terada
- Department of Pathology, University of Florida College of Medicine, Gainesville, Florida, USA
| | - L Lin
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA
| | - M Riel-Mehan
- Animated Cell, Allen Institute for Cell Biology, Seattle, Washington, USA
| | - T P Do
- Animated Cell, Allen Institute for Cell Biology, Seattle, Washington, USA
| | - M Kubo
- RIKEN Center for Integrative Medical Science, Yokohama, Japan
| | - S W Yee
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA
| | - G T Johnson
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.,Animated Cell, Allen Institute for Cell Biology, Seattle, Washington, USA
| | - K M Giacomini
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.,Institute for Human Genetics, University of California, San Francisco, San Francisco, California, USA
| |
Collapse
|
35
|
Kubo M, Tanaka H, Maki S, Nii M, Murabayashi N, Osato K, Kamimoto Y, Umekawa T, Kondo E, Ikeda T. Safety and dose-finding trial of tadalafil administered for fetal growth restriction: A phase-1 clinical study. J Obstet Gynaecol Res 2017; 43:1159-1168. [DOI: 10.1111/jog.13345] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2016] [Revised: 01/30/2017] [Accepted: 02/19/2017] [Indexed: 11/30/2022]
Affiliation(s)
- Michiko Kubo
- Department of Obstetrics and Gynecology; Mie University School of Medicine; Mie Japan
| | - Hiroaki Tanaka
- Department of Obstetrics and Gynecology; Mie University School of Medicine; Mie Japan
| | - Shintaro Maki
- Department of Obstetrics and Gynecology; Mie University School of Medicine; Mie Japan
| | - Masafumi Nii
- Department of Obstetrics and Gynecology; Mie University School of Medicine; Mie Japan
| | - Nao Murabayashi
- Department of Obstetrics and Gynecology; Mie University School of Medicine; Mie Japan
| | - Kazuhiro Osato
- Department of Obstetrics and Gynecology; Mie University School of Medicine; Mie Japan
| | - Yuki Kamimoto
- Department of Obstetrics and Gynecology; Mie University School of Medicine; Mie Japan
| | - Takashi Umekawa
- Department of Obstetrics and Gynecology; Mie University School of Medicine; Mie Japan
| | - Eiji Kondo
- Department of Obstetrics and Gynecology; Mie University School of Medicine; Mie Japan
| | - Tomoaki Ikeda
- Department of Obstetrics and Gynecology; Mie University School of Medicine; Mie Japan
| |
Collapse
|
36
|
Toyo‐oka L, Mahasirimongkol S, Yanai H, Mushiroda T, Wattanapokayakit S, Wichukchinda N, Yamada N, Smittipat N, Juthayothin T, Palittapongarnpim P, Nedsuwan S, Kantipong P, Takahashi A, Kubo M, Sawanpanyalert P, Tokunaga K. Strain‐based
HLA
association analysis identified
HLA‐DRB1
*09:01
associated with modern strain tuberculosis. HLA 2017; 90:149-156. [DOI: 10.1111/tan.13070] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2017] [Revised: 05/18/2017] [Accepted: 05/22/2017] [Indexed: 01/08/2023]
Affiliation(s)
- L. Toyo‐oka
- Medical Genetics Center, Medical Life Science Institute Department of Medical Sciences, Ministry of Public Health Nonthaburi Thailand
- Department of Human Genetics, Graduate School of Medicine The University of Tokyo Tokyo Japan
| | - S. Mahasirimongkol
- Medical Genetics Center, Medical Life Science Institute Department of Medical Sciences, Ministry of Public Health Nonthaburi Thailand
| | - H. Yanai
- Fukujuji Hospital Japan Anti‐Tuberculosis Association (JATA) Kiyose Japan
- Research Institute of Tuberculosis Japan Anti‐Tuberculosis Association (JATA) Kiyose Japan
| | - T. Mushiroda
- Laboratory for Pharmacogenomics RIKEN Center for Integrative Medical Sciences Yokohama Japan
| | - S. Wattanapokayakit
- Medical Genetics Center, Medical Life Science Institute Department of Medical Sciences, Ministry of Public Health Nonthaburi Thailand
| | - N. Wichukchinda
- Medical Genetics Center, Medical Life Science Institute Department of Medical Sciences, Ministry of Public Health Nonthaburi Thailand
| | - N. Yamada
- Research Institute of Tuberculosis Japan Anti‐Tuberculosis Association (JATA) Kiyose Japan
| | - N. Smittipat
- Tuberculosis Research Laboratory, National Center for Genetic Engineering and Biotechnology National Science and Technology Development Agency, Thailand Science Park (TSP) Pathum Thani Thailand
| | - T. Juthayothin
- Tuberculosis Research Laboratory, National Center for Genetic Engineering and Biotechnology National Science and Technology Development Agency, Thailand Science Park (TSP) Pathum Thani Thailand
| | - P. Palittapongarnpim
- Department of Microbiology, Faculty of Science Mahidol University Bangkok Thailand
| | - S. Nedsuwan
- Chiangrai Prachanukroh Hospital Ministry of Public Health Chiang Rai Thailand
| | - P. Kantipong
- Chiangrai Prachanukroh Hospital Ministry of Public Health Chiang Rai Thailand
| | - A. Takahashi
- Laboratory for Statistical Analysis RIKEN Center for Integrative Medical Sciences Yokohama Japan
| | - M. Kubo
- Laboratory for Genotyping Development RIKEN Center for Integrative Medical Sciences Yokohama Japan
| | - P. Sawanpanyalert
- Health Technical Office Ministry of Public Health Nonthaburi Thailand
| | - K. Tokunaga
- Department of Human Genetics, Graduate School of Medicine The University of Tokyo Tokyo Japan
| |
Collapse
|
37
|
Tanaka H, Kubo M, Nii M, Maki S, Umekawa T, Ikeda T. Treatment using tadalafil for severe pre-eclampsia with fetal growth restriction. J Obstet Gynaecol Res 2017; 43:1205-1208. [PMID: 28503744 DOI: 10.1111/jog.13335] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2016] [Revised: 02/14/2017] [Accepted: 02/25/2017] [Indexed: 11/27/2022]
Abstract
For severe pre-eclampsia (PE) with fetal growth restriction (FGR), the only effective treatment is early delivery of the placenta. Clinicians are often forced to end the pregnancy because of maternal indications. We report a case of severe PE with FGR in which the PE was temporarily improved and pregnancy successfully prolonged with tadalafil, a phosphodiesterase 5 inhibitor. A 35-year-old primigravid woman presented at 27 3/7 weeks of gestation with severe PE and FGR. After commencing tadalafil administration, biochemical and angiogenic markers improved. Thereafter, hypertension and proteinuria temporarily improved. Importantly, the pregnancy was prolonged by 14 days after the initiation of tadalafil administration. Tadalafil may be a novel treatment for severe PE with FGR to prolong pregnancy.
Collapse
Affiliation(s)
- Hiroaki Tanaka
- Department of Obstetrics and Gynecology, Mie University School of Medicine, Mie, Japan
| | - Michiko Kubo
- Department of Obstetrics and Gynecology, Mie University School of Medicine, Mie, Japan
| | - Masafumi Nii
- Department of Obstetrics and Gynecology, Mie University School of Medicine, Mie, Japan
| | - Sintarou Maki
- Department of Obstetrics and Gynecology, Mie University School of Medicine, Mie, Japan
| | - Takashi Umekawa
- Department of Obstetrics and Gynecology, Mie University School of Medicine, Mie, Japan
| | - Tomoaki Ikeda
- Department of Obstetrics and Gynecology, Mie University School of Medicine, Mie, Japan
| |
Collapse
|
38
|
Mori H, Kubo M, Yamaguti R, Nishimura R, Osako T, Arima N, Okumura Y, Okido M, Yamada M, Kai M, Kishimoto J, Oda Y, Nakamura M. Abstract P6-07-05: PD-L1 expression and decreased tumor-infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-07-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Tumor microenvironment has been considered to have an active role in determining the aggressiveness of tumor cells. Recently, programmed cell death ligand-1 (PD-L1) expression or tumor-infiltrating lymphocytes (TILs) are known to be an important prognostic factor of breast cancer. However, the correlation of expression of PD-L1 and TILs still remains unclear. Triple-negative breast cancer (TNBC) is a heterogeneous tumor that encompasses many different subclasses. Further identification of these subclasses is necessary in order to predict prognosis and choose appropriate treatments. Our goal was to correlate PD-L1 expression with clinicopathological features including TILs by using a large cohort of TNBCs.
Patients and Methods: This study included 248 patients with primary TNBC who underwent resection without neoadjuvant chemotherapy at our three hospitals between January 2004 and December 2014. The tumor subtypes were routinely determined immunohistochemically by using resected specimens. IHC scoring for PD-L1 expression was defined in reference to that for HER2 expression. PD-L1 positivity was defined as both IHC 2+ and IHC 3+. Cases were defined as high if stromal TILs ≥50% according to recommendations by the International TILs Working Group.
Results: Of the 248 TNBCs, PD-L1 were expressed as positive in 103 (41.5%) tumors, and TILs were highly present in 118 (47.6%) tumors. PD-L1 expression was significantly correlated with higher levels of TILs (P < 0.0001). There was no significant difference when the prognosis of the patients who had PD-L1-positive tumors was compared with that of the patients who had PD-L1-negative tumors (P = 0.56 in recurrence free survival [RFS] and P = 0.13 in overall survival [OS]). Meanwhile, the patients with high-TILs tumors had longer OS, compared to the patients with low-TILs tumors (P = 0.55 in RFS and P = 0.016 in OS). The analysis in the cross effect between PD-L1 expression and TILs using cox proportional hazards model demonstrated that the PD-L1 expression and TILs are not independent factors(P = 0.0018 in RFS and P = 0.015 in OS). The PD-L1-positive group with low-TILs had significantly shorter survival than the PD-L1-positive group with high-TILs (hazard ratio [HR] = 4.7, 95% confidence interval [CI] 1.6–12.7, P = 0.0067 in RFS; HR = 8.4, 95%CI 2.3-30.3, P = 0.0019 in OS).
Conclusions: Our data indicated that PD-L1 expression was related to higher levels of TILs, and PD-L1-positive tumors with low-TILs were associated with poor prognosis in patients with TNBCs. It is proposed that these biomarkers may be of use for predicting their prognosis and essential in the subclassification of TNBCs.
Citation Format: Mori H, Kubo M, Yamaguti R, Nishimura R, Osako T, Arima N, Okumura Y, Okido M, Yamada M, Kai M, Kishimoto J, Oda Y, Nakamura M. PD-L1 expression and decreased tumor-infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-07-05.
Collapse
Affiliation(s)
- H Mori
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - M Kubo
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - R Yamaguti
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - R Nishimura
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - T Osako
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - N Arima
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - Y Okumura
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - M Okido
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - M Yamada
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - M Kai
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - J Kishimoto
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - Y Oda
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| | - M Nakamura
- Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan; Kurume Medical Center, Kurume City, Japan; Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto Shinto General Hospital, Kumamoto City, Japan; Kumamoto City Hospital, Kumamoto City, Japan; Hamanomachi Hospital, Fukuoka City, Japan; Faculty of Medical Sciences, Kyushu University, Fukuoka City, Japan
| |
Collapse
|
39
|
Cairns J, Ingle J, Dudenkov T, Kalari K, Buzdar A, Kubo M, Robson M, Ellis M, Goss P, Shepherd L, Goetz M, Weinshilboum R, Wang L. Abstract PD1-04: CSMD1 SNPs selectively affect anastrozole response in postmenopausal breast cancer patients. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-pd1-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Based on prospective clinical trials, there is no evidence for differences in efficacy between the 3 aromatase inhibitors (AIs) anastrozole, exemestane, and letrozole. The purpose of this study was to identify germline genetic variants associated with response to AIs and to help identify novel mechanisms associated with drug disease efficacy.
METHODS: A genome-wide association study (GWAS) was performed for 624 patients (Steroids 2015;99:32-38) to identify SNPs associated with estrogen level change in women with estrogen receptor (ER) positive breast cancer treated with anastrozole. Replication of associated SNPs was performed in a GWAS from the MA.27 trial that compared adjuvant anastrozole and exemestane treatment of post-menopausal women with ER+ breast cancer. Functional studies were subsequently performed to determine SNP effects and underlying mechanisms.
RESULTS: Our initial GWAS identified SNPs within CSMD1 that were associated with changes in estrogen levels during anastrozole therapy. An additional SNP in CSMD1 was also associated with breast cancer events in CCTG MA.27. Functionally, we showed that CSMD1 regulates CYP19 expression in a SNP-, and in an anastrozole- dependent fashion. These phenomena were not observed for either letrozole or exemestane. In MA.27, an anastrozole- specific effect was also seen with the minor allele having a protective effect on time to distant metastasis (HR=0.49, p=0.00259), but this was not the case for exemestane (HR=0.71, p=0.111). Our in vitro functional studies indicated that overexpression of CSMD1 sensitized anastrozole or letrozole resistant cells to anastrozole but not to the other two AIs. The SNP in CSMD1 that was associated with increased CSMD1 and CYP19 expression levels increased anastrozole sensitivity, but not letrozole or exemestane in lymphoblastoid cell lines (LCLs) homozygous for either WT or variant CSMD1 SNP genotypes. Based on these observations, we explored whether anastrozole has additional mechanisms beyond its function as a CYP19 inhibitor. Utilizing an estrogen response element (ERE) luciferase reporter assay in a CYP19 CRISPR knockout breast cancer T47D cell line and a surface plasmon resonance (SPR) assay, we found that anastrozole can also function as an ERα agonist, and can bind to, and result in, proteasome dependent ERα degradation, especially in the presence of E2. Treatment of these CYP19 CRISPR knockout cells with anastrozole in the presence of increasing concentrations of E2 results in greater sensitivity compared with anastrozole alone, while the addition of E2, as expected, does not improve letrozole or exemestane sensitivity. These same observations were also seen in letrozole and anastrazole resistant cells.
CONCLUSIONS: Our findings suggest that anastrozole might be more effective than letrozole or exemestane in patients with the CSMD1 SNP. Furthermore, anastrozole can function as an ERα agonist, binding to ERα and resulting in its degradation, especially in the presence of E2. These findings should help to make it possible to develop precision endocrine therapies for women who are candidates for AIs.
Citation Format: Cairns J, Ingle J, Dudenkov T, Kalari K, Buzdar A, Kubo M, Robson M, Ellis M, Goss P, Shepherd L, Goetz M, Weinshilboum R, Wang L. CSMD1 SNPs selectively affect anastrozole response in postmenopausal breast cancer patients [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr PD1-04.
Collapse
Affiliation(s)
- J Cairns
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - J Ingle
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - T Dudenkov
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - K Kalari
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - A Buzdar
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - M Kubo
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - M Robson
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - M Ellis
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - P Goss
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - L Shepherd
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - M Goetz
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - R Weinshilboum
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| | - L Wang
- Mayo Clinic, Rochester, MN; The University of Texas MD Anderson Cancer Center, Houston, TX; Riken Center for Integrative Medical Science, Yokohama, Japan; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor Cancer Center, Houston, TX; Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Kingston, ON, Canada
| |
Collapse
|
40
|
Dujic T, Zhou K, Yee SW, van Leeuwen N, de Keyser CE, Javorský M, Goswami S, Zaharenko L, Hougaard Christensen MM, Out M, Tavendale R, Kubo M, Hedderson MM, van der Heijden AA, Klimčáková L, Pirags V, Kooy A, Brøsen K, Klovins J, Semiz S, Tkáč I, Stricker BH, Palmer C, 't Hart LM, Giacomini KM, Pearson ER. Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis. Clin Pharmacol Ther 2017; 101:763-772. [PMID: 27859023 PMCID: PMC5425333 DOI: 10.1002/cpt.567] [Citation(s) in RCA: 68] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2016] [Revised: 09/26/2016] [Accepted: 11/06/2016] [Indexed: 12/25/2022]
Abstract
Therapeutic response to metformin, a first-line drug for type 2 diabetes (T2D), is highly variable, in part likely due to genetic factors. To date, metformin pharmacogenetic studies have mainly focused on the impact of variants in metformin transporter genes, with inconsistent results. To clarify the significance of these variants in glycemic response to metformin in T2D, we performed a large-scale meta-analysis across the cohorts of the Metformin Genetics Consortium (MetGen). Nine candidate polymorphisms in five transporter genes (organic cation transporter [OCT]1, OCT2, multidrug and toxin extrusion transporter [MATE]1, MATE2-K, and OCTN1) were analyzed in up to 7,968 individuals. None of the variants showed a significant effect on metformin response in the primary analysis, or in the exploratory secondary analyses, when patients were stratified according to possible confounding genotypes or prescribed a daily dose of metformin. Our results suggest that candidate transporter gene variants have little contribution to variability in glycemic response to metformin in T2D.
Collapse
Affiliation(s)
- T Dujic
- Department of Biochemistry and Clinical Analysis, Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.,Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, UK
| | - K Zhou
- Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, UK
| | - S W Yee
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA
| | - N van Leeuwen
- Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, The Netherlands
| | - C E de Keyser
- Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.,Inspectorate of Healthcare, Utrecht, The Netherlands
| | - M Javorský
- Department of Internal Medicine 4, Faculty of Medicine, Šafárik University, Košice, Slovakia.,Pasteur University Hospital, Košice, Slovakia
| | - S Goswami
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA
| | - L Zaharenko
- Latvian Biomedical Research and Study Centre, Riga, Latvia
| | | | - M Out
- Treant Zorggroep, Location Bethesda, Hoogeveen, The Netherlands.,Bethesda Diabetes Research Centre, Hoogeveen, The Netherlands
| | - R Tavendale
- Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, UK
| | - M Kubo
- Core for Genomic Medicine, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - M M Hedderson
- Division of Research, Kaiser Permanente Northern California, Oakland, California, USA
| | - A A van der Heijden
- Department of General Practice, EMGO+ Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands
| | - L Klimčáková
- Department of Medical Biology, Faculty of Medicine, Šafárik University, Košice, Slovakia
| | - V Pirags
- Latvian Biomedical Research and Study Centre, Riga, Latvia
| | - A Kooy
- Treant Zorggroep, Location Bethesda, Hoogeveen, The Netherlands.,Bethesda Diabetes Research Centre, Hoogeveen, The Netherlands
| | - K Brøsen
- Department of Public Health, Clinical Pharmacology and Pharmacy, University of Southern Denmark, Odense, Denmark
| | - J Klovins
- Latvian Biomedical Research and Study Centre, Riga, Latvia
| | - S Semiz
- Department of Biochemistry and Clinical Analysis, Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.,International University of Sarajevo, Faculty of Engineering and Natural Sciences, Sarajevo, Bosnia and Herzegovina
| | - I Tkáč
- Department of Internal Medicine 4, Faculty of Medicine, Šafárik University, Košice, Slovakia.,Pasteur University Hospital, Košice, Slovakia
| | - B H Stricker
- Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.,Inspectorate of Healthcare, Utrecht, The Netherlands.,Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Cna Palmer
- Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, UK
| | - L M 't Hart
- Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, The Netherlands.,Department of Molecular Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.,Department of Epidemiology and Biostatistics, EMGO+ Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands
| | - K M Giacomini
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.,Institute for Human Genetics, University of California, San Francisco, San Francisco, California, USA
| | - E R Pearson
- Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, UK
| |
Collapse
|
41
|
Suzuki K, Furuhashi M, Kawamura T, Kubo M, Osato K, Yamawaki T. Comparing Papanicolaou test results obtained during pregnancy and post-partum. J Obstet Gynaecol Res 2017; 43:705-709. [DOI: 10.1111/jog.13268] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2016] [Revised: 10/27/2016] [Accepted: 11/20/2016] [Indexed: 11/29/2022]
Affiliation(s)
- Kazuhiro Suzuki
- Department of Obstetrics and Gynecology; Japanese Red Cross Nagoya Daiichi Hospital; Nagoya Japan
| | - Madoka Furuhashi
- Department of Obstetrics and Gynecology; Japanese Red Cross Nagoya Daiichi Hospital; Nagoya Japan
| | - Takuya Kawamura
- Department of Obstetrics and Gynecology; Japanese Red Cross Ise Hospital; Ise Japan
| | - Michiko Kubo
- Department of Obstetrics and Gynecology; Mie University Hospital; Tsu Japan
| | - Kazuhiro Osato
- Department of Obstetrics and Gynecology; Mie University Hospital; Tsu Japan
| | - Takaharu Yamawaki
- Department of Obstetrics and Gynecology; Japanese Red Cross Ise Hospital; Ise Japan
| |
Collapse
|
42
|
Kubo M, Umekawa T, Maekawa Y, Tanaka H, Nii M, Murabayashi N, Osato K, Kamimoto Y, Ikeda T. Retrospective study of tadalafil for fetal growth restriction: Impact on maternal and perinatal outcomes. J Obstet Gynaecol Res 2016; 43:291-297. [DOI: 10.1111/jog.13218] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2016] [Revised: 08/26/2016] [Accepted: 09/23/2016] [Indexed: 01/09/2023]
Affiliation(s)
- Michiko Kubo
- Department of Obstetrics and Gynecology; Mie University Graduate School of Medicine; Tsu Japan
| | - Takashi Umekawa
- Department of Obstetrics and Gynecology; Mie University Graduate School of Medicine; Tsu Japan
| | - Yuka Maekawa
- Department of Obstetrics and Gynecology; National Organization Mie Chuo Medical Center; Tsu Japan
| | - Hiroaki Tanaka
- Department of Obstetrics and Gynecology; Mie University Graduate School of Medicine; Tsu Japan
| | - Masafumi Nii
- Department of Obstetrics and Gynecology; Mie University Graduate School of Medicine; Tsu Japan
| | - Nao Murabayashi
- Department of Obstetrics and Gynecology; Mie University Graduate School of Medicine; Tsu Japan
| | - Kazuhiro Osato
- Department of Obstetrics and Gynecology; Mie University Graduate School of Medicine; Tsu Japan
| | - Yuki Kamimoto
- Department of Obstetrics and Gynecology; Mie University Graduate School of Medicine; Tsu Japan
| | - Tomoaki Ikeda
- Department of Obstetrics and Gynecology; Mie University Graduate School of Medicine; Tsu Japan
| |
Collapse
|
43
|
Nawata T, Kubo M, Okuda S, Omoto M, Yujiri T, Kanda T, Yano M. Successful treatment with intravenous cyclophosphamide for anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis associated with myelodysplastic syndrome. Scand J Rheumatol 2016; 46:496-498. [DOI: 10.1080/03009742.2016.1253770] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- T Nawata
- Department of Medicine and Clinical Science, Division of Cardiology and Clinical Immunology, Yamaguchi University Graduate School of Medicine, Ube, Japan
| | - M Kubo
- Department of Medicine and Clinical Science, Division of Cardiology and Clinical Immunology, Yamaguchi University Graduate School of Medicine, Ube, Japan
| | - S Okuda
- Department of Medicine and Clinical Science, Division of Cardiology and Clinical Immunology, Yamaguchi University Graduate School of Medicine, Ube, Japan
| | - M Omoto
- Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Ube, Japan
| | - T Yujiri
- Department of Medicine and Clinical Science, Division of Endocrinology, Metabolism, Hematological Science and Therapeutics, Yamaguchi University Graduate School of Medicine, Ube, Japan
| | - T Kanda
- Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Ube, Japan
| | - M Yano
- Department of Medicine and Clinical Science, Division of Cardiology and Clinical Immunology, Yamaguchi University Graduate School of Medicine, Ube, Japan
| |
Collapse
|
44
|
Gupta M, Neavin D, Liu D, Biernacka J, Hall-Flavin D, Bobo WV, Frye MA, Skime M, Jenkins GD, Batzler A, Kalari K, Matson W, Bhasin SS, Zhu H, Mushiroda T, Nakamura Y, Kubo M, Wang L, Kaddurah-Daouk R, Weinshilboum RM. TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics. Mol Psychiatry 2016; 21:1717-1725. [PMID: 26903268 PMCID: PMC5003027 DOI: 10.1038/mp.2016.6] [Citation(s) in RCA: 85] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/04/2015] [Revised: 12/07/2015] [Accepted: 01/07/2016] [Indexed: 01/01/2023]
Abstract
Millions of patients suffer from major depressive disorder (MDD), but many do not respond to selective serotonin reuptake inhibitor (SSRI) therapy. We used a pharmacometabolomics-informed pharmacogenomics research strategy to identify genes associated with metabolites that were related to SSRI response. Specifically, 306 MDD patients were treated with citalopram or escitalopram and blood was drawn at baseline, 4 and 8 weeks for blood drug levels, genome-wide single nucleotide polymorphism (SNP) genotyping and metabolomic analyses. SSRI treatment decreased plasma serotonin concentrations (P<0.0001). Baseline and plasma serotonin concentration changes were associated with clinical outcomes (P<0.05). Therefore, baseline and serotonin concentration changes were used as phenotypes for genome-wide association studies (GWAS). GWAS for baseline plasma serotonin concentrations revealed a genome-wide significant (P=7.84E-09) SNP cluster on chromosome four 5' of TSPAN5 and a cluster across ERICH3 on chromosome one (P=9.28E-08) that were also observed during GWAS for change in serotonin at 4 (P=5.6E-08 and P=7.54E-07, respectively) and 8 weeks (P=1.25E-06 and P=3.99E-07, respectively). The SNPs on chromosome four were expression quantitative trait loci for TSPAN5. Knockdown (KD) and overexpression (OE) of TSPAN5 in a neuroblastoma cell line significantly altered the expression of serotonin pathway genes (TPH1, TPH2, DDC and MAOA). Chromosome one SNPs included two ERICH3 nonsynonymous SNPs that resulted in accelerated proteasome-mediated degradation. In addition, ERICH3 and TSPAN5 KD and OE altered media serotonin concentrations. Application of a pharmacometabolomics-informed pharmacogenomic research strategy, followed by functional validation, indicated that TSPAN5 and ERICH3 are associated with plasma serotonin concentrations and may have a role in SSRI treatment outcomes.
Collapse
Affiliation(s)
- M Gupta
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA
| | - D Neavin
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA
| | - D Liu
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA
| | - J Biernacka
- Department of Biomedical Statistics and Bioinformatics – Genetics and Bioinformatics, Mayo Clinic, Rochester, MN, USA
| | - D Hall-Flavin
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA
| | - W V Bobo
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA
| | - M A Frye
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA
| | - M Skime
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA
| | - G D Jenkins
- Department of Biomedical Statistics and Bioinformatics – Genetics and Bioinformatics, Mayo Clinic, Rochester, MN, USA
| | - A Batzler
- Department of Biomedical Statistics and Bioinformatics – Genetics and Bioinformatics, Mayo Clinic, Rochester, MN, USA
| | - K Kalari
- Department of Biomedical Statistics and Bioinformatics – Genetics and Bioinformatics, Mayo Clinic, Rochester, MN, USA
| | - W Matson
- Bedford VA Medical Center, Bedford, MA, USA
| | - S S Bhasin
- Bedford VA Medical Center, Bedford, MA, USA
| | - H Zhu
- Department of Psychiatry and Behavioral Medicine, Duke Institute for Brain Sciences, Duke University, Durham, NC, USA
| | - T Mushiroda
- RIKEN Center for Genomic Medicine, Yokohama, Japan
| | - Y Nakamura
- Department of Medicine, University of Chicago, Chicago, IL, USA
| | - M Kubo
- RIKEN Center for Genomic Medicine, Yokohama, Japan
| | - L Wang
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA
| | - R Kaddurah-Daouk
- Department of Psychiatry and Behavioral Medicine, Duke Institute for Brain Sciences, Duke University, Durham, NC, USA
| | - R M Weinshilboum
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA,Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. E-mail:
| |
Collapse
|
45
|
Saito T, Shimazaki Y, Kiyohara Y, Kato I, Kubo M, Iida M, Koga T. The Severity of Periodontal Disease is Associated with the Development of Glucose Intolerance in Non-diabetics: The Hisayama Study. J Dent Res 2016; 83:485-90. [PMID: 15153457 DOI: 10.1177/154405910408300610] [Citation(s) in RCA: 134] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Inflammation is hypothesized to play a significant role in the development of type 2 diabetes; however, reports on clinical inflammatory conditions are limited. Studies have suggested that periodontitis affects glucose control in diabetics. This community-based study examined the relationship between periodontitis and glucose tolerance status, including changes in status. The relationship between periodontal condition and the results of a 75-g oral glucose tolerance test was examined in 961 adults in 1998. Deep pockets (mean pocket depth > 2.0 mm) were significantly associated with impaired glucose tolerance and with diabetes as compared with shallow pockets (< 1.3 mm). In the subgroup with normal glucose tolerance 10 years previously, subjects who subsequently developed impaired glucose tolerance were significantly more likely to have deep pockets. Deep pockets were closely related to current glucose tolerance status and the development of glucose intolerance.
Collapse
Affiliation(s)
- T Saito
- Department of Preventive Dentistry, Kyushu University Faculty of Dental Science, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan.
| | | | | | | | | | | | | |
Collapse
|
46
|
Sakamoto M, Osato K, Kubo M, Nii M, Tanaka H, Murabayashi N, Umekawa T, Kamimoto Y, Ikeda T. Early-onset fetal growth restriction treated with the long-acting phosphodiesterase-5 inhibitor tadalafil: a case report. J Med Case Rep 2016; 10:317. [PMID: 27821175 PMCID: PMC5100077 DOI: 10.1186/s13256-016-1098-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2016] [Accepted: 10/12/2016] [Indexed: 11/10/2022] Open
Abstract
Background Severe early-onset fetal growth restriction occurs in 0.4 % of all pregnancies, and the prognoses of these patients are dismal. Severely growth-restricted fetuses (far below 500 g) are thought to be nonviable. Since there have not been effective treatments for such fetal patients, obstetricians have simply tried to identify the optimal timing for their delivery. There are a few reports suggesting that the phosphodiesterase type 5 inhibitor sildenafil has some limited beneficial effects on fetal growth, but there are no such reports on tadalafil, another derivative phosphodiesterase type 5 inhibitor which has a much longer half-life than sildenafil. Here we present a case in which the administration of tadalafil to the mother revived the arrested growth and severe oligohydramnios of the very prematurely growth-restricted fetus. Case presentation We describe a case of early-onset fetal growth restriction with oligohydramnios in a 41-year-old primigravida Japanese woman who was treated with tadalafil (20-mg tablet daily) from 22 weeks’ gestational age. Ten days after the initiation of the tadalafil therapy, the amniotic fluid level rose and the weight of the fetus began to increase. A 1024-g baby boy was delivered by cesarean at 32 weeks’ gestation. The z-score for fetal head circumference had increased from −2.2 to −1.2, whereas the z-score of the femur legth was decreased to −4.3, indicating that tadalafil preferentially increased the blood flow to important organs. Conclusions We achieved two positive results by administering tadalafil to the mother carrying a severely growth-restricted fetus with oligohydramnios. First, the z-scores of head circumference and abdominal circumference had at first declined but started to rise after the tadalafil administration. Second, the amniotic fluid, which was emptied before the tadalafil treatment, recovered to normal range with this treatment. Tadalafil administration to mothers could be a promising therapy to reverse severe fetal growth restriction and oligohydramnios.
Collapse
Affiliation(s)
- Mito Sakamoto
- Mie University Hospital, 174-2 Edobashi, Tsu City, Mie, Japan.
| | - Kazuhiro Osato
- Mie University Hospital, 174-2 Edobashi, Tsu City, Mie, Japan
| | - Michiko Kubo
- Mie University Hospital, 174-2 Edobashi, Tsu City, Mie, Japan
| | - Masafumi Nii
- Mie University Hospital, 174-2 Edobashi, Tsu City, Mie, Japan
| | - Hiroaki Tanaka
- Mie University Hospital, 174-2 Edobashi, Tsu City, Mie, Japan
| | - Nao Murabayashi
- Mie University Hospital, 174-2 Edobashi, Tsu City, Mie, Japan
| | - Takashi Umekawa
- Mie University Hospital, 174-2 Edobashi, Tsu City, Mie, Japan
| | - Yuki Kamimoto
- Mie University Hospital, 174-2 Edobashi, Tsu City, Mie, Japan
| | - Tomoaki Ikeda
- Mie University Hospital, 174-2 Edobashi, Tsu City, Mie, Japan
| |
Collapse
|
47
|
Otomi Y, Shinya T, Uyama N, Arai Y, Miyamoto K, Takechi K, Kubo M, Otsuka H, Harada M. The physiological accumulation of FDG in the muscles in relation to the side of intravenous administration. Jpn J Radiol 2016; 35:53-60. [DOI: 10.1007/s11604-016-0597-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2016] [Accepted: 10/23/2016] [Indexed: 12/13/2022]
|
48
|
Toriyabe K, Kitamura A, Maki S, Kubo M, Nii M, Tanaka K, Nishioka M, Watanabe J, Takayama E, Maezawa T, Tanaka H, Murabayashi N, Osato K, Kamimoto Y, Ikeda T. A case of non-primary cytomegalovirus infection in a pregnant woman whose fetus developed congenital cytomegalovirus infection. J Reprod Immunol 2016. [DOI: 10.1016/j.jri.2016.10.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
49
|
Goswami S, Yee SW, Xu F, Sridhar SB, Mosley JD, Takahashi A, Kubo M, Maeda S, Davis RL, Roden DM, Hedderson MM, Giacomini KM, Savic RM. A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin. Clin Pharmacol Ther 2016; 100:537-547. [PMID: 27415606 PMCID: PMC5534241 DOI: 10.1002/cpt.428] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2016] [Revised: 06/20/2016] [Accepted: 06/22/2016] [Indexed: 12/20/2022]
Abstract
One-third of type-2 diabetic patients respond poorly to metformin. Despite extensive research, the impact of genetic and nongenetic factors on long-term outcome is unknown. In this study we combine nonlinear mixed effect modeling with computational genetic methodologies to identify predictors of long-term response. In all, 1,056 patients contributed their genetic, demographic, and long-term HbA1c data. The top nine variants (of 12,000 variants in 267 candidate genes) accounted for approximately one-third of the variability in the disease progression parameter. Average serum creatinine level, age, and weight were determinants of symptomatic response; however, explaining negligible variability. Two single nucleotide polymorphisms (SNPs) in CSMD1 gene (rs2617102, rs2954625) and one SNP in a pharmacologically relevant SLC22A2 gene (rs316009) influenced disease progression, with minor alleles leading to less and more favorable outcomes, respectively. Overall, our study highlights the influence of genetic factors on long-term HbA1c response and provides a computational model, which when validated, may be used to individualize treatment.
Collapse
Affiliation(s)
- S Goswami
- University of California, San Francisco, San Francisco, California, USA
| | - S W Yee
- University of California, San Francisco, San Francisco, California, USA
| | - F Xu
- Kaiser Permanente Northern California, Oakland, California, USA
| | - S B Sridhar
- Kaiser Permanente Northern California, Oakland, California, USA
| | - J D Mosley
- Vanderbilt University, Nashville, Tennessee, USA
| | - A Takahashi
- RIKEN Institute, Center for Genomic Medicine, Saitama, Japan
| | - M Kubo
- RIKEN Institute, Center for Genomic Medicine, Saitama, Japan
| | - S Maeda
- RIKEN Institute, Center for Genomic Medicine, Saitama, Japan
| | - R L Davis
- Kaiser Permanente Georgia, Atlanta, Georgia, USA
- Center for Biomedical Informatics, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA
| | - D M Roden
- Vanderbilt University, Nashville, Tennessee, USA
| | - M M Hedderson
- Kaiser Permanente Northern California, Oakland, California, USA
| | - K M Giacomini
- University of California, San Francisco, San Francisco, California, USA.
| | - R M Savic
- University of California, San Francisco, San Francisco, California, USA.
| |
Collapse
|
50
|
Chang SW, McDonough CW, Gong Y, Johnson TA, Tsunoda T, Gamazon ER, Perera MA, Takahashi A, Tanaka T, Kubo M, Pepine CJ, Johnson JA, Cooper-DeHoff RM. Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes. Pharmacogenomics J 2016; 18:106-112. [PMID: 27670767 PMCID: PMC5368017 DOI: 10.1038/tpj.2016.67] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/14/2015] [Revised: 07/11/2016] [Accepted: 08/25/2016] [Indexed: 01/14/2023]
Abstract
We conducted a discovery genome-wide association study with expression quantitative trait loci (eQTL) annotation of new-onset diabetes (NOD) among European Americans, who were exposed to a calcium channel blocker-based strategy (CCB strategy) or a β-blocker-based strategy (β-blocker strategy) in the INternational VErapamil SR Trandolapril STudy. Replication of the top signal from the SNP*treatment interaction analysis was attempted in Hispanic and African Americans, and a joint meta-analysis was performed (total 334 NOD cases and 806 matched controls). PLEKHH2 rs11124945 at 2p21 interacted with antihypertensive exposure for NOD (meta-analysis p=5.3×10−8). rs11124945 G allele carriers had lower odds for NOD when exposed to the β-blocker strategy compared with the CCB strategy [OR=0.38 (0.24-0.60), p=4.0×10−5], while A/A homozygotes exposed to the β-blocker strategy had increased odds for NOD compared with the CCB strategy [OR=2.02 (1.39-2.92), p=2.0×10−4]. eQTL annotation of the 2p21 locus provides functional support for regulating gene expression.
Collapse
Affiliation(s)
- S-W Chang
- Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL, USA
| | - C W McDonough
- Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL, USA
| | - Y Gong
- Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL, USA
| | - T A Johnson
- Laboratory for Medical Science Mathematics, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan
| | - T Tsunoda
- Laboratory for Medical Science Mathematics, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan.,Department of Medical Science Mathematics, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan
| | - E R Gamazon
- Division of Genetic Medicine, Department of Medicine, Vanderbilt University, Nashville, TN, USA
| | - M A Perera
- Department of Medicine, University of Chicago, Chicago, IL, USA
| | - A Takahashi
- Laboratory for Statistical Analysis, SNP Research Center, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - T Tanaka
- Laboratory for Cardiovascular Diseases, SNP Research Center, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - M Kubo
- Laboratory for Genotyping Development, SNP Research Center, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - C J Pepine
- Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
| | - J A Johnson
- Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL, USA.,Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
| | - R M Cooper-DeHoff
- Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL, USA.,Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
| |
Collapse
|